NATIONAL QUALITY FORUM

Measure Evaluation 4.1 January 2010

This form contains the measure information submitted by stewards. Blank fields indicate no information was provided. Attachments also may have been submitted and are provided to reviewers. The sub-criteria and most of the footnotes from the <u>evaluation criteria</u> are provided in Word comments and will appear if your cursor is over the highlighted area (or in the margin if your Word program is set to show revisions in balloons). Hyperlinks to the evaluation criteria and ratings are provided in each section.

TAP/Workgroup (if utilized): Complete all yellow highlighted areas of the form. Evaluate the extent to which each sub-criterion is met. Based on your evaluation, summarize the strengths and weaknesses in each section.

Note: If there is no TAP or workgroup, the SC also evaluates the sub-criteria (yellow highlighted areas).

Steering Committee: Complete all **pink** highlighted areas of the form. Review the workgroup/TAP assessment of the sub-criterion, noting any areas of disagreement; then evaluate the extent to which each major criterion is met; and finally, indicate your recommendation for the endorsement. Provide the rationale for your ratings.

Evaluation ratings of the extent to which the criteria are met

C = Completely (unquestionably demonstrated to meet the criterion)

P = Partially (demonstrated to partially meet the criterion)

M = Minimally (addressed BUT demonstrated to only minimally meet the criterion)

N = Not at all (NOT addressed; OR incorrectly addressed; OR demonstrated to NOT meet the criterion)

NA = Not applicable (only an option for a few sub-criteria as indicated)

(for NQF staff use) NQF Review #: PSM-026-10	NQF Project: Patient Safety Measures
MEASURE	DESCRIPTIVE INFORMATION
De.1 Measure Title: Patient(s) with HIV infection reported months.	taking antiretroviral medications that had a CBC in last 6
De.2 Brief description of measure: This measure antiretroviral medications that had at least one C	e identifies HIV-infected persons, 2 years of age or older, taking BC test in last 6 months of the report period.
1.1-2 Type of Measure: process De.3 If included in a composite or paired with another measure, please identify composite or paired measure Does not apply	
De.4 National Priority Partners Priority Area: sa De.5 IOM Quality Domain: safety De.6 Consumer Care Need: Staying Healthy	afety

CONDITIONS FOR CONSIDERATION BY NQF	
Four conditions must be met before proposed measures may be considered and evaluated for suitability as voluntary consensus standards:	NQF Staff
 A. The measure is in the public domain or an intellectual property (measure steward agreement) is signed. Public domain only applies to governmental organizations. All non-government organizations must sign a measure steward agreement even if measures are made publicly and freely available. A.1 Do you attest that the measure steward holds intellectual property rights to the measure and the right to use aspects of the measure owned by another entity (e.g., risk model, code set)? Yes 	
A.2 Indicate if Proprietary Measure (as defined in measure steward agreement): proprietary measure A.3 Measure Steward Agreement: agreement signed and submitted	
A.4 Measure Steward Agreement attached: Measure Steward Addendum_Ingenix 012010-	

633997868366262970.doc	
B. The measure owner/steward verifies there is an identified responsible entity and process to maintain and update the measure on a schedule that is commensurate with the rate of clinical innovation, but at least every 3 years. Yes, information provided in contact section	B Y N
 C. The intended use of the measure includes <u>both</u> public reporting <u>and</u> quality improvement. Purpose: public reporting, quality improvement Payment Incentive, Accountability 	C Y N
 D. The requested measure submission information is complete. Generally, measures should be fully developed and tested so that all the evaluation criteria have been addressed and information needed to evaluate the measure is provided. Measures that have not been tested are only potentially eligible for a time-limited endorsement and in that case, measure owners must verify that testing will be completed within 12 months of endorsement. D.1Testing: Yes, fully developed and tested D.2 Have NQF-endorsed measures been reviewed to identify if there are similar or related measures? Yes 	D Y N
(for NQF staff use) Have all conditions for consideration been met? Staff Notes to Steward (<i>if submission returned</i>):	Met Y N
Staff Notes to Reviewers (issues or questions regarding any criteria):	
Staff Reviewer Name(s):	

TAP/Workgroup Reviewer Name:	
Steering Committee Reviewer Name:	
1. IMPORTANCE TO MEASURE AND REPORT	
Extent to which the specific measure focus is important to making significant gains in health care quality (safety, timeliness, effectiveness, efficiency, equity, patient-centeredness) and improving health outcomes for a specific high impact aspect of healthcare where there is variation in or overall poor performance. <i>Measures must be judged to be important to measure and report in order to be evaluated against the remaining criteria</i> . (evaluation criteria) 1a. High Impact	Eval Ratin g
(for NQF staff use) Specific NPP goal:	
 1a.1 Demonstrated High Impact Aspect of Healthcare: patient/societal consequences of poor quality 1a.2 1a.3 Summary of Evidence of High Impact: More than 1 million Americans are infected with HIV (1). Since 1996, the availability of highly active antiretroviral therapy (HAART) has been associated with significant declines in morbidity related to AIDS-related complications (1). As such, the use of HAART has increased over the past decade. HAART has been associated with a variety of adverse events (2). Often, these adverse events can be addressed through drug discontinuation or other interventions. Therefore, routine laboratory monitoring for specific adverse events is recommended (2). 	
 1a.4 Citations for Evidence of High Impact: 1. CDC. HIV/AIDS in the United States. Available from the CDC Web site: http://www.cdc.gov/hiv/resources/factsheets/us.htm (Accessed January 8, 2010). 2. DHHS Panel on Guidelines for the use of Antiretroviral Agents in HIV-infected Adults and Adolescents. (December 1, 2009). Available from AIDSinfo Web site: http://aidsinfo.nih.gov/ (Accessed January 8, 2010). 	1a C P M N
 1b. Opportunity for Improvement 1b.1 Benefits (improvements in quality) envisioned by use of this measure: CBC monitoring can identify the presence of a HAART-related adverse events. Identification of an adverse event can be addressed 	1b C P M

1c.8 Citations for Evidence (other than guidelines): DHHS guideline - see 1c.10	M N
1c.7 Summary of Controversy/Contradictory Evidence: There is no controversial evidence related to this recommendation.	1c C□ P□
1c.6 Method for rating evidence:	
whom): There is no strength of evidence provided with this recommendation. This recommendation is baesd on consensus expert opinion.	
1c.5 Rating of strength/quality of evidence (also provide narrative description of the rating and by	
Since laboratory adverse events can be serious (e.g., anemia, life-threatening neutropenia), monitoring is an essential part of the care plan.	
The 2009 DHHS panel guidelines recommend a CBC with differential monitoring every 3-6 months for anyone on highly active antiretroviral therapy (HAART). The rationale is that monitoring will reduce preventable adverse events, improve HAART compliance, and ultimately improve outcomes such as quality of life and viral control.	
1c.4 Summary of Evidence (as described in the criteria; for outcomes, summarize any evidence that healthcare services/care processes influence the outcome): The Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) is a working group of the Office of AIDS Research Advisory Council (OARAC). Annually, this group publishes guidelines for the management of patients infected with HIV. For the first time in November 2008, the guidelines stated specific recommendations for laboratory tests to obtain for HIV-infected patients at baseline and while receiving antiretroviral therapy to monitor for safety and treatment responses. These recommendations remained in the most recent December 2009 guidelines.	
1c.2-3. Type of Evidence: evidence based guideline	
1c.1 Relationship to Outcomes (For non-outcome measures, briefly describe the relationship to desired outcome. For outcomes, describe why it is relevant to the target population): The primary outcome is to improve the safety and efficacy of HAART. CBC monitoring allows detection or adverse events that can be managed with drug discontinuation or other interventions. This can prevent more serious adverse events, improve HAART compliance, and ultimately improve outcomes such as quality of life and viral control.	
1c. Outcome or Evidence to Support Measure Focus	
1b.5 Citations for data on Disparities:	
1b.4 Summary of Data on disparities by population group: None	
1b.3 Citations for data on performance gap: Ingenix EBM Connect benchmark results, September 2009	
 1b.2 Summary of data demonstrating performance gap (variation or overall poor performance) across providers: Using a geographically diverse 15 million member benchmark database (this database represents predominately a commercial population less than 65 year of age) the compliance rate was 44.4 percent, indicating a clear gap in care and opportunity for care improvement. 	
HAART compliance, and ultimately improve outcomes such as quality of life and viral control.	
through drug discontinuation or other interventions. This can prevent more serious adverse events, improve	N_

1c.9 Quote the Specific guideline recommendation (including guideline number and/or page number):	
Table 3, page 6 states:"CBC w/ differential""every 3-6 months."	
 1c.10 Clinical Practice Guideline Citation: DHHS Panel on Guidelines for the use of Antiretroviral Agents in HIV-infected Adults and Adolescents. (December 1, 2009). Available from AIDSinfo Web site: http://aidsinfo.nih.gov/ (Accessed January 8, 2010). 1c.11 National Guideline Clearinghouse or other URL: 	
http://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&Search=Off&GuidelineID=7& ClassID=1	
1c.12 Rating of strength of recommendation (also provide narrative description of the rating and by whom):	
There is no strength of evidence provided with this recommendation. This recommendation is baesd on consensus expert opinion.	
1c.13 Method for rating strength of recommendation (If different from <u>USPSTF system</u> , also describe rating and how it relates to USPSTF):	
1c.14 Rationale for using this guideline over others: The DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents is an internationally recognized group that provides comprehensive recommendations for the management of HIV-infected individuals. This is considered the gold standard guideline by U.S. providers who manage HIV-infected patients.	
TAP/Workgroup: What are the strengths and weaknesses in relation to the sub-criteria for Importance to Measure and Report?	1
Steering Committee: Was the threshold criterion, <i>Importance to Measure and Report</i> , met? Rationale:	1 Y N
2. SCIENTIFIC ACCEPTABILITY OF MEASURE PROPERTIES	
Extent to which the measure, <u>as specified</u> , produces consistent (reliable) and credible (valid) results about the quality of care when implemented. (<u>evaluation criteria</u>)	Eval Ratin g
2a. MEASURE SPECIFICATIONS	
2a. MEASURE SPECIFICATIONS S.1 Do you have a web page where current detailed measure specifications can be obtained? S.2 If yes, provide web page URL:	
S.1 Do you have a web page where current detailed measure specifications can be obtained?	
S.1 Do you have a web page where current detailed measure specifications can be obtained? S.2 If yes, provide web page URL:	-
 S.1 Do you have a web page where current detailed measure specifications can be obtained? S.2 If yes, provide web page URL: 2a. Precisely Specified 2a.1 Numerator Statement (Brief, text description of the numerator - what is being measured about the target population, e.g. target condition, event, or outcome): Patients who are diagnosed with HIV infection and are taking an antiretroviral medication, who have had a CBC test during the following time period: last 180 days of the report period through 90 days after the end 	
 S.1 Do you have a web page where current detailed measure specifications can be obtained? S.2 If yes, provide web page URL: 2a. Precisely Specified 2a.1 Numerator Statement (Brief, text description of the numerator - what is being measured about the target population, e.g. target condition, event, or outcome): Patients who are diagnosed with HIV infection and are taking an antiretroviral medication, who have had a CBC test during the following time period: last 180 days of the report period through 90 days after the end of the report period 2a.2 Numerator Time Window (The time period in which cases are eligible for inclusion in the numerator): 	2a- specs C□
 S.1 Do you have a web page where current detailed measure specifications can be obtained? S.2 If yes, provide web page URL: 2a. Precisely Specified 2a.1 Numerator Statement (Brief, text description of the numerator - what is being measured about the target population, e.g. target condition, event, or outcome): Patients who are diagnosed with HIV infection and are taking an antiretroviral medication, who have had a CBC test during the following time period: last 180 days of the report period through 90 days after the end of the report period 2a.2 Numerator Time Window (The time period in which cases are eligible for inclusion in the numerator): Last 180 days of the report period 2a.3 Numerator Details (All information required to collect/calculate the numerator, including all codes, logic, and definitions): Patients who have had a test for CBC (code set PR0013) during the following time period: last 180 days of 	specs

PR0013	CBC	80055
PR0013	CBC	85021
PR0013	CBC	85022
PR0013	CBC	85023
PR0013	CBC	85024
PR0013	CBC	85025
PR0013	CBC	85027
PR0013	CBC	85031

2a.4 Denominator Statement (*Brief, text description of the denominator - target population being measured***):**

Patients two years of age or older who are diagnosed with HIV infection and who are being actively treated with an antiretroviral medication

2a.5 Target population gender: Male, Female

2a.6 Target population age range: Patients two years of age or older at the end of the report period

2a.7 Denominator Time Window (The time period in which cases are eligible for inclusion in the denominator):

The 24 months prior to the end of the report period for confirmation that the patient had HIV infection; last 120 days of the report period through 90 days after the end of the report period for confirmation that the patient was actively taking antiretroviral medication

2a.8 Denominator Details (All information required to collect/calculate the denominator - the target population being measured - including all codes, logic, and definitions):

Criteria for inclusion in the denominator are as follows:

1. All males or females that are two years of age or older at the end of the report period

2. Patient must have been continuously enrolled in medical benefits throughout the 12 months prior to the end of the report period AND pharmacy benefit plan for 6 months prior to the end of the report period. The standard EBM Connect® enrollment break logic allows unlimited breaks in coverage of no more than 45 days and no breaks greater than 45 days.

3. The patient is listed in the Disease Registry Input File for this condition OR

During the 24 months prior to the end of the report period, the patient has two or more of the following services or events, at least 14 days apart, with a diagnosis of HIV (code set DX0065):

- Professional Encounter code set (PR0107 or RV0107)
- Professional Supervision code set (PR0108)
- Facility Event Confinement/Admission (i.e., hospital admission)
- Facility Event Emergency Room
- Facility Event Outpatient Surgery

4. The patient must have filled a prescription for an antiretroviral medication (code sets RX-2, RX-10, RX-18, RX-40, RX-47, RX-57, RX-67, RX-83, RX-86, RX-102, RX-103, RX-104, RX-112, RX-115, RX-129, RX-169, RX-206, RX-230, RX-404, RX-405) during the last 120 days of the report period through 90 days after the end of the report period, with a duration of treatment greater than 90 days.

Code Set Code Set Description Diagnosis Code

			2
DX0065	HIV/AIDS ()42	
DX0065	HIV/AIDS ()79.	53
DX0065	HIV/AIDS	80	
Code Set	Code Set Description	n	Procedure Code
PR0107	Professional encoun	ter	99201
PR0107	Professional encoun	ter	99202
PR0107	Professional encoun	ter	99203
PR0107	Professional encoun	ter	99204
PR0107	Professional encoun	ter	99205
PR0107	Professional encoun	ter	99211
PR0107	Professional encoun	ter	99212

PR0107	Professional encounter	99213
PR0107	Professional encounter	99214
PR0107	Professional encounter	99215
PR0107	Professional encounter	99217
PR0107	Professional encounter	99218
PR0107	Professional encounter	99219
PR0107	Professional encounter	99220
PR0107	Professional encounter	99221
PR0107	Professional encounter	99222
PR0107	Professional encounter	99223
PR0107	Professional encounter	99231
PR0107	Professional encounter	99232
PR0107	Professional encounter	99233
PR0107	Professional encounter	99234
PR0107	Professional encounter	99235
PR0107 PR0107		99235 99236
PR0107 PR0107	Professional encounter	99230 99238
	Professional encounter	
PR0107	Professional encounter	99239
PR0107	Professional encounter	99241
PR0107	Professional encounter	99242
PR0107	Professional encounter	99243
PR0107	Professional encounter	99244
PR0107	Professional encounter	99245
PR0107	Professional encounter	99251
PR0107	Professional encounter	99252
PR0107	Professional encounter	99253
PR0107	Professional encounter	99254
PR0107	Professional encounter	99255
PR0107	Professional encounter	99261
PR0107	Professional encounter	99262
PR0107	Professional encounter	99263
PR0107	Professional encounter	99271
PR0107	Professional encounter	99272
PR0107	Professional encounter	99273
PR0107	Professional encounter	99274
PR0107	Professional encounter	99275
PR0107	Professional encounter	99281
PR0107	Professional encounter	99282
PR0107	Professional encounter	99283
PR0107	Professional encounter	99284
PR0107	Professional encounter	99285
PR0107	Professional encounter	99301
PR0107	Professional encounter	99302
PR0107	Professional encounter	99303
PR0107	Professional encounter	99304
PR0107	Professional encounter	99305
PR0107	Professional encounter	99306
PR0107	Professional encounter	99307
PR0107	Professional encounter	99308
PR0107	Professional encounter	99309
PR0107	Professional encounter	99310
PR0107	Professional encounter	99311
PR0107	Professional encounter	99312
PR0107	Professional encounter	99313
PR0107	Professional encounter	99315
PR0107	Professional encounter	99316
PR0107	Professional encounter	99318
PR0107	Professional encounter	99341

-	
PR0107	Professional encounter 99342
PR0107	Professional encounter 99343
PR0107	Professional encounter 99344
PR0107	Professional encounter 99345
PR0107	Professional encounter 99347
PR0107	Professional encounter 99348
PR0107	Professional encounter 99349
PR0107	Professional encounter 99350
PR0107	Professional encounter 99381
PR0107	Professional encounter 99382
PR0107	Professional encounter 99383
PR0107	Professional encounter 99384
PR0107	Professional encounter 99385
PR0107	Professional encounter 99386
PR0107	Professional encounter 99387
PR0107	Professional encounter 99391
PR0107	Professional encounter 99392
PR0107	Professional encounter 99392
PR0107 PR0107	Professional encounter 99394
PR0107 PR0107	Professional encounter 99395
PR0107 PR0107	Professional encounter 99396
PR0107 PR0107	
PR0107 PR0107	
PR0107 PR0107	Professional encounter 99401 Professional encounter 99402
PR0107 PR0107	Professional encounter 99402 Professional encounter 99403
PR0107 PR0107	Professional encounter 99403
PR0107 PR0107	Professional encounter 99404
PR0107 PR0107	Professional encounter 99411
PR0107	Professional encounter 99420
PR0107	Professional encounter 99429
PR0107	Professional encounter S0270
PR0107	Professional encounter S0270
PR0107	Professional encounter S0277
PR0107	Professional encounter S0272
Code Set	Code Set Description Procedure Code
PR0108	Professional supervision 99321
PR0108	Professional supervision 99322
PR0108	Professional supervision 99323
PR0108	Professional supervision 99324
PR0108	Professional supervision 99325
PR0108	Professional supervision 99326
PR0108	Professional supervision 99327
PR0108	Professional supervision 99328
PR0108	Professional supervision 99331
PR0108	Professional supervision 99332
PR0108	Professional supervision 99333
PR0108	Professional supervision 99334
PR0108	Professional supervision 99335
PR0108	Professional supervision 99336
PR0108	Professional supervision 99337
PR0108	Professional supervision 99339
PR0108	Professional supervision 99340
PR0108	Professional supervision 99371
PR0108	Professional supervision 99372
PR0108	Professional supervision 99373
PR0108	Professional supervision 99374
PR0108	Professional supervision 99375
	Provide a state of the state of

Abacavir-containing med Abacavir-containing med	lication lication lication lication lication lication lication lication lication	35356010930 35356011606 35356011660 54569488300 54569519100 54569539000 54569559400 54868452200 54868452201 54868560000 68258915801
Abacavir-containing med Abacavir-containing med	lication lication lication lication lication lication lication lication lication	35356010930 35356011606 35356011660 54569488300 54569519100 54569539000 54569559400 54868452200 54868452201 54868560000
Abacavir-containing med Abacavir-containing med Abacavir-containing med Abacavir-containing med Abacavir-containing med Abacavir-containing med Abacavir-containing med Abacavir-containing med Abacavir-containing med Abacavir-containing med	lication lication lication lication lication lication lication lication	35356010930 35356011606 35356011660 54569488300 54569519100 54569539000 54569559400 54868452200 54868452201
Abacavir-containing med Abacavir-containing med Abacavir-containing med Abacavir-containing med Abacavir-containing med Abacavir-containing med Abacavir-containing med Abacavir-containing med	lication lication lication lication lication lication lication	35356010930 35356011606 35356011660 54569488300 54569519100 54569539000 54569559400 54868452200
Abacavir-containing mec Abacavir-containing mec Abacavir-containing mec Abacavir-containing mec Abacavir-containing mec Abacavir-containing mec Abacavir-containing mec	lication lication lication lication lication lication	35356010930 35356011606 35356011660 54569488300 54569519100 54569539000
Abacavir-containing mec Abacavir-containing mec Abacavir-containing mec Abacavir-containing mec Abacavir-containing mec Abacavir-containing mec	lication lication lication lication lication	35356010930 35356011606 35356011660 54569488300 54569519100
Abacavir-containing mec Abacavir-containing mec Abacavir-containing mec Abacavir-containing mec Abacavir-containing mec	lication lication lication lication	35356010930 35356011606 35356011660 54569488300
Abacavir-containing mec Abacavir-containing mec Abacavir-containing mec Abacavir-containing mec	lication lication lication	35356010930 35356011606 35356011660
Abacavir-containing mec Abacavir-containing mec Abacavir-containing mec	lication lication	35356010930 35356011606
Abacavir-containing mec Abacavir-containing mec	lication	35356010930
Abacavir-containing med		
	lication	33330010700
Abacavii "Containing med		35356007560
Abacavir-containing mec Abacavir-containing mec		35356007506 35356007560
Abacavir-containing med		00173074200
Abacavir-containing med		00173069120
Abacavir-containing mec		00173069100
Abacavir-containing mec		00173066400
Abacavir-containing mec		00173066101
Abacavir-containing mec		00173066100
et Rx code set description		ndc
Professional encounter	0983	
Professional encounter	0981	
Professional encounter	0529	
Professional encounter	0528	
Professional encounter	0526	
Professional encounter	0525	
Professional encounter	0524	
Professional encounter	0523	
Professional encounter	0522	
Professional encounter Professional encounter	0520	
Professional encounter	0519 0520	
Professional encounter	0517	
Professional encounter	0516	
Professional encounter	0515	
Professional encounter	0514	
Professional encounter	0513	
Professional encounter	0512	
Professional encounter	0511	
Professional encounter	0510	
Code Set Description	Revenue Code	
Professional supervision G	0182	
Professional supervision G		
Professional supervision G		
Professional supervision G		
Professional supervision 9	9379	
Professional supervision 9	9377	
I	Professional supervision 9 Professional supervision 9	Professional supervision 99377 Professional supervision 99378 Professional supervision 99379

			-
RX-10	Amprenavir and Fosamprenavir	00173067200	
RX-10	Amprenavir and Fosamprenavir	00173067900	
RX-10	Amprenavir and Fosamprenavir	00173068700	
RX-10	Amprenavir and Fosamprenavir	00173072100	
RX-10	Amprenavir and Fosamprenavir	00173072700	
RX-10	Amprenavir and Fosamprenavir	35356006706	
RX-10	Amprenavir and Fosamprenavir	35356006760	
RX-10	Amprenavir and Fosamprenavir	54569481300	
RX-10	Amprenavir and Fosamprenavir	54569555000	
RX-10	Amprenavir and Fosamprenavir	54868495400	
RX-10	Amprenavir and Fosamprenavir	67263038760	
KA-10	Amprenavir and rosamprenavir	07203038700	
	et Rx code set description	ndc	
RX-18	Atazanavir (Reyataz)	00003362212	
RX-18	Atazanavir (Reyataz)	00003362312	
RX-18	Atazanavir (Reyataz)	00003362412	
RX-18	Atazanavir (Reyataz)	00003363112	
RX-18	Atazanavir (Reyataz)	35356006806	
RX-18	Atazanavir (Reyataz)	35356006860	
RX-18	Atazanavir (Reyataz)	35356011406	
RX-18	Atazanavir (Reyataz)	35356011430	
RX-18	Atazanavir (Reyataz)	35356020760	
RX-18	Atazanavir (Reyataz)	54569553000	
RX-18	Atazanavir (Reyataz)	54569553200	
RX-18	Atazanavir (Reyataz)	54868485400	
RX-18	Atazanavir (Reyataz)	54868485700	
RX-18	Atazanavir (Reyataz)	54868583800	
RX-18	Atazanavir (Reyataz)	54898485400	
RX-18	Atazanavir (Reyataz)	67263023060	
RX-18	Atazanavir (Reyataz)	68258914201	
	Acuzuliu (Regucuz)	00230711201	
Dy codo co	b. Dy code cot description	nde	
	et Rx code set description	ndc	
RX-40	Didanosine	00087661443	
RX-40	Didanosine	00087661543	
RX-40	Didanosine	00087661643	
RX-40	Didanosine	00087661743	
RX-40	Didanosine	00087662443	
RX-40	Didanosine	00087662643	
RX-40	Didanosine	00087662743	
RX-40	Didanosine	00087662843	
RX-40	Didanosine	00087663241	
RX-40	Didanosine	00087663341	
RX-40	Didanosine	00087665001	
RX-40	Didanosine	00087665101	
RX-40	Didanosine	00087665201	
RX-40	Didanosine	00087665301	
RX-40	Didanosine	00087666515	
RX-40	Didanosine	00087667117	
RX-40	Didanosine	00087667217	
RX-40	Didanosine	00087667317	
RX-40	Didanosine	00087667417	
RX-40	Didanosine	00555058801	
RX-40	Didanosine	00555058901	
RX-40	Didanosine	00555059001	
RX-40	Didanosine	35356018630	
RX-40	Didanosine	35356025930	
RX-40	Didanosine	51129299902	
RX-40	Didanosine	54569365700	
L			

RX-40	Didanosine	54569397100	
RX-40	Didanosine	54569431300	
RX-40	Didanosine	54569431301	
RX-40 RX-40	Didanosine	54569451400	
RX-40 RX-40			
	Didanosine	54569490500	
RX-40	Didanosine	54569517600	
RX-40	Didanosine	54569550400	
RX-40	Didanosine	54569564200	
RX-40	Didanosine	54569564300	
RX-40	Didanosine	54868250200	
RX-40	Didanosine	54868250202	
RX-40	Didanosine	54868336400	
RX-40	Didanosine	54868466600	
RX-40	Didanosine	54868546400	
RX-40	Didanosine	54868559500	
RX-40	Didanosine	62584004611	
RX-40	Didanosine	62584004621	
RX-40	Didanosine	62584004811	
RX-40	Didanosine	62584004821	
RX-40	Didanosine	65862031030	
RX-40	Didanosine	65862031130	
RX-40	Didanosine	65862031230	
RX-40	Didanosine	65862031330	
Rx code se	t Rx code set description	ndc	
RX-47	Enfuvirtide	00004038039	
RX-47	Enfuvirtide	35356020660	
RX-47	Enfuvirtide	54569578100	
	Emavireide	5-507570100	
Rx code se	t Rx code set description	ndc	
RX-57	Indinavir	00006057062	
RX-57	Indinavir	00006057142	
RX-57	Indinavir	00006057143	
RX-57	Indinavir	00006057301	
RX-57	Indinavir	00006057318	
RX-57	Indinavir	00006057340	
RX-57	Indinavir	00006057342	
RX-57	Indinavir	00006057354	
RX-57	Indinavir	00006057362	
RX-57	Indinavir	00006057465	
RX-57	Indinavir	16590006418	
RX-57	Indinavir	16590006430	
RX-57	Indinavir	16590006460	
RX-57	Indinavir	16590006490	
RX-57	Indinavir	21695036618	
RX-57	Indinavir	35356013918	
RX-57	Indinavir	35356013960	
RX-57	Indinavir	52959050712	
RX-57	Indinavir	52959050718	
RX-57	Indinavir	52959050724	
RX-57	Indinavir	52959050730	
RX-57	Indinavir	54569862000	
RX-57	Indinavir	54569862001	
RX-57	Indinavir	54868411300	
RX-57	Indinavir	55175520901	
RX-57	Indinavir	55887023030	
RX-57	Indinavir	55887023060	
RX-57	Indinavir	55887023090	

DV 57	The Device Provider	5004/0/0000	
RX-57	Indinavir	58016069900	
RX-57	Indinavir	58016069930	
RX-57	Indinavir	58016069960	
RX-57	Indinavir	58016069990	
RX-57	Indinavir	62682101701	
	et Rx code set description	ndc	
RX-67	Lamivudine-containing medication	00173047001	
RX-67	Lamivudine-containing medication	00173047100	
RX-67	Lamivudine-containing medication	00173059500	
RX-67	Lamivudine-containing medication	00173059502	
RX-67	Lamivudine-containing medication	00173069100	
RX-67	Lamivudine-containing medication	00173069120	
RX-67	Lamivudine-containing medication	00173071400	
RX-67	Lamivudine-containing medication	00173074200	
RX-67	Lamivudine-containing medication	16590006106	
RX-67	Lamivudine-containing medication	21695036706	
RX-67	Lamivudine-containing medication	21695084606	
RX-67	Lamivudine-containing medication	23490708706	
RX-67	Lamivudine-containing medication	35356006530	
RX-67	Lamivudine-containing medication	35356006624	
RX-67	Lamivudine-containing medication	35356010906	
RX-67	Lamivudine-containing medication	35356010930	
RX-67	Lamivudine-containing medication	35356011606	
RX-67	Lamivudine-containing medication	35356011660	
RX-67	Lamivudine-containing medication	49999006206	
RX-67	Lamivudine-containing medication	49999006210	
RX-67	Lamivudine-containing medication	49999006260	
RX-67	Lamivudine-containing medication	49999011906	
RX-67		49999011960	
RX-67	Lamivudine-containing medication	52959050802	
RX-67	Lamivudine-containing medication	52959050802	
RX-67	Lamivudine-containing medication		
RX-67	Lamivudine-containing medication	52959050806 52050050808	
	Lamivudine-containing medication	52959050808	
RX-67	Lamivudine-containing medication	52959050814	
RX-67	Lamivudine-containing medication	52959050815	
RX-67	Lamivudine-containing medication	52959050860	
RX-67	Lamivudine-containing medication	52959054602	
RX-67	Lamivudine-containing medication	52959054603	
RX-67	Lamivudine-containing medication	52959054604	
RX-67	Lamivudine-containing medication	52959054606	
RX-67	Lamivudine-containing medication	52959054608	
RX-67	Lamivudine-containing medication	52959054610	
RX-67	Lamivudine-containing medication	52959054614	
RX-67	Lamivudine-containing medication	52959054615	
RX-67	Lamivudine-containing medication	52959054620	
RX-67	Lamivudine-containing medication	52959054628	
RX-67	Lamivudine-containing medication	54569422100	
RX-67	Lamivudine-containing medication	54569422101	
RX-67	Lamivudine-containing medication	54569422102	
RX-67	Lamivudine-containing medication	54569433300	
RX-67	Lamivudine-containing medication	54569452400	
RX-67	Lamivudine-containing medication	54569452401	
RX-67	Lamivudine-containing medication	54569452402	
RX-67	Lamivudine-containing medication	54569452403	
RX-67	Lamivudine-containing medication	54569519100	
RX-67	Lamivudine-containing medication	54569550100	
RX-67	Lamivudine-containing medication	54569559400	
L			

RX-67	Lamivudine-containing medication	54868369300	
RX-67	Lamivudine-containing medication	54868369302	
RX-67	Lamivudine-containing medication	54868411400	
RX-67	Lamivudine-containing medication	54868411406	
RX-67	Lamivudine-containing medication	54868541600	
RX-67	Lamivudine-containing medication	54868560000	
RX-67	Lamivudine-containing medication	55045230803	
RX-67	Lamivudine-containing medication	55045285606	
RX-67	Lamivudine-containing medication	55175520706	
RX-67	Lamivudine-containing medication	55289038904	
RX-67		55289038904	
RX-67	Lamivudine-containing medication	55289038906	
RX-67	Lamivudine-containing medication	55289038914	
	Lamivudine-containing medication		
RX-67	Lamivudine-containing medication	55887023130	
RX-67	Lamivudine-containing medication	55887023160	
RX-67	Lamivudine-containing medication	55887023190	
RX-67	Lamivudine-containing medication	58016068900	
RX-67	Lamivudine-containing medication	58016068930	
RX-67	Lamivudine-containing medication	58016068960	
RX-67	Lamivudine-containing medication	58016068990	
RX-67	Lamivudine-containing medication	58016069800	
RX-67	Lamivudine-containing medication	58016069830	
RX-67	Lamivudine-containing medication	58016069860	
RX-67	Lamivudine-containing medication	58016069890	
RX-67	Lamivudine-containing medication	58016079500	
RX-67	Lamivudine-containing medication	58016079530	
RX-67	Lamivudine-containing medication	58016079560	
RX-67 RX-67	Lamivudine-containing medication	58016079590 60760059504	
RX-67	Lamivudine-containing medication Lamivudine-containing medication	60760059514	
RX-67		62682101606	
RX-67	Lamivudine-containing medication Lamivudine-containing medication	62682104801	
RX-67	Lamivudine-containing medication	66267050906	
RX-67	Lamivudine-containing medication	67263025860	
RX-67	Lamivudine-containing medication	68030606001	
RX-67	Lamivudine-containing medication	68030606401	
RX-67	Lamivudine-containing medication	68030728301	
RX-67	Lamivudine-containing medication	68115009006	
RX-67	Lamivudine-containing medication	68258910801	
RX-67	Lamivudine-containing medication	68258915801	
10(0)		00230713001	
Rx code s	et Rx code set description	ndc	
RX-83	Nelfinavir	35356011701	
RX-83	Nelfinavir	49999043103	
RX-83	Nelfinavir	52959028930	
RX-83	Nelfinavir	54569454300	
RX-83	Nelfinavir	54569454301	
RX-83	Nelfinavir	54569454302	
RX-83	Nelfinavir	54569454303	
RX-83	Nelfinavir	54569454304	
RX-83	Nelfinavir	54569454305	
RX-83	Nelfinavir	54569454306	
RX-83	Nelfinavir	54569557300	
RX-83	Nelfinavir	54868394700	
RX-83	Nelfinavir	54868506100	
RX-83	Nelfinavir	55045268206	
RX-83	Nelfinavir	55045268208	
RX-83	Nelfinavir	55175520807	
L			

NQF	#PSM-	026-10
-----	-------	--------

RX-83 Netfinavir 60760001063 RX-83 Netfinavir 63010001027 RX-83 Netfinavir 63010001030 RX-83 Netfinavir 63010001030 RX-83 Netfinavir 6301000170 RX-83 Netfinavir 6301000170 RX-83 Netfinavir 6301000170 RX-83 Netfinavir 63010002740 RX-84 Non-nucleoside reverse transcriptase inhibitors 0000975/601 RX-86 Non-nucleoside reverse transcriptase inhibitors 0000975/601 RX-86 Non-nucleoside reverse transcriptase inhibitors 00054464725 RX-86 Non-nucleoside reverse transcriptase inhibitors 0005604730 RX-86 Non-nucleoside reverse transcriptase inhibitors 005604730 RX-86 Non-nucleoside reverse transcriptase inhibitors 005604730 RX-86 Non-nucleoside reverse transcriptase inhibitors 005604730 RX-86 Non-nucleoside reverse transcriptase inhibitors 00567004601 RX-86 Non-nucleoside reverse transcriptase inhibitors 0057004661 RX-86 Non-nucleoside reverse transcriptase inhibitors 00597004661			NQF #PSM-020
RX-83Netfinavir60760001063RX-83Netfinavir63010001027RX-83Netfinavir63010001030RX-83Netfinavir63010002770RX-83Netfinavir63010002770RX-83Netfinavir63010002770RX-84Non-nucleoside reverse transcriptase inhibitors0009375103RX-86Non-nucleoside reverse transcriptase inhibitors0009439058RX-86Non-nucleoside reverse transcriptase inhibitors00054464725RX-86Non-nucleoside reverse transcriptase inhibitors00054664725RX-86Non-nucleoside reverse transcriptase inhibitors0005647730RX-86Non-nucleoside reverse transcriptase inhibitors00056047030RX-86Non-nucleoside reverse transcriptase inhibitors00056047030RX-86Non-nucleoside reverse transcriptase inhibitors00056047030RX-86Non-nucleoside reverse transcriptase inhibitors0005604730RX-86Non-nucleoside reverse transcriptase inhibitors0005604730RX-86Non-nucleoside reverse transcriptase inhibitors00597004601RX-86Non-nucleoside reverse transcriptase inhibitors00597004601RX-86Non-nucleoside reverse transcriptase inhibitors00597004601RX-86Non-nucleoside reverse transcriptase inhibitors3335000460RX-86Non-nucleoside reverse transcriptase inhibitors3335000460RX-86Non-nucleoside reverse transcriptase inhibitors3335007160RX-86Non-nucleoside reverse transcriptase inhibitors3335007160 </td <td>RX-83</td> <td>Nelfinavir 55289047</td> <td>727</td>	RX-83	Nelfinavir 55289047	727
RX-83 Netfinavir 63010001027 RX-83 Netfinavir 63010001130 RX-83 Netfinavir 63010002770 RX-83 Netfinavir 6301002770 RX-83 Netfinavir 6301002770 RX-83 Netfinavir 63030728401 Rx-84 Non-nucleoside reverse transcriptase inhibitors 00009757601 RX-86 Non-nucleoside reverse transcriptase inhibitors 00054404721 RX-86 Non-nucleoside reverse transcriptase inhibitors 00054464725 RX-86 Non-nucleoside reverse transcriptase inhibitors 00056047330 RX-86 Non-nucleoside reverse transcriptase inhibitors 00056047030 RX-86 Non-nucleoside reverse transcriptase inhibitors 00567004601 RX-86 Non-nucleoside reverse transcriptase inhibitors 00597004601 RX-86 Non-nucleoside reverse transcriptase inhibitors 0335000406 RX-86 Non-nucle	RX-83	Nelfinavir 607600010	018
RX-83 Netfinavir 63010001100 RX-83 Netfinavir 63010002770 RX-83 Netfinavir 63030728401 RX-84 Non-nucleoside reverse transcriptase inhibitors 00009376103 RX-86 Non-nucleoside reverse transcriptase inhibitors 00009376103 RX-86 Non-nucleoside reverse transcriptase inhibitors 00009376103 RX-86 Non-nucleoside reverse transcriptase inhibitors 00054464725 RX-86 Non-nucleoside reverse transcriptase inhibitors 0005404730 RX-86 Non-nucleoside reverse transcriptase inhibitors 00056047330 RX-86 Non-nucleoside reverse transcriptase inhibitors 0005604730 RX-86 Non-nucleoside reverse transcriptase inhibitors 0056051030 RX-86 Non-nucleoside reverse transcriptase inhibitors 0056051030 RX-86 Non-nucleoside reverse transcriptase inhibitors 0057004661 RX-86 Non-nucleoside reverse transcriptase inhibitors 00597004661 RX-86 Non-nucleoside reverse transcriptase inhibitors 0335600406 RX-86 Non-nucleoside reverse transcriptase inhibitors 3335600460 RX-86 Non-nucleoside reverse transcrip	RX-83	Nelfinavir 607600010	063
RX-83 Netfinavir 63010001190 RX-83 Netfinavir 63030728401 RX-83 Netfinavir 68030728401 RX-84 Non-nucleoside reverse transcriptase inhibitors 00009757611 RX-86 Non-nucleoside reverse transcriptase inhibitors 00009757611 RX-86 Non-nucleoside reverse transcriptase inhibitors 0009757611 RX-86 Non-nucleoside reverse transcriptase inhibitors 00054464725 RX-86 Non-nucleoside reverse transcriptase inhibitors 0005647300 RX-86 Non-nucleoside reverse transcriptase inhibitors 00056047301 RX-86 Non-nucleoside reverse transcriptase inhibitors 0056047302 RX-86 Non-nucleoside reverse transcriptase inhibitors 0056047301 RX-86 Non-nucleoside reverse transcriptase inhibitors 0059704661 RX-86 Non-nucleoside reverse transcriptase inhibitors 0059704661 RX-86 Non-nucleoside reverse transcriptase inhibitors 0597004661 RX-86 Non-nucleoside reverse transcriptase inhibitors 333500430 RX-86 Non-nucleoside reverse transcriptase inhibitors 333500430 RX-86 Non-nucleoside reverse transcriptase	RX-83	Nelfinavir 630100010	027
RX-83 Netfinavir 63010002770 RX-83 Netfinavir 68030728401 Rx-60 set Rx-code set Rx-code set Rx-code set Rx-code set Rx-code set Rx-84 Non-nucleoside reverse transcriptase inhibitors 00009376103 RX-86 Non-nucleoside reverse transcriptase inhibitors 00054464721 RX-86 Non-nucleoside reverse transcriptase inhibitors 00054646725 RX-86 Non-nucleoside reverse transcriptase inhibitors 00054664725 RX-86 Non-nucleoside reverse transcriptase inhibitors 00056047300 RX-86 Non-nucleoside reverse transcriptase inhibitors 00056047492 RX-86 Non-nucleoside reverse transcriptase inhibitors 0056051030 RX-86 Non-nucleoside reverse transcriptase inhibitors 00597004661 RX-86 Non-nucleoside reverse transcriptase inhibitors 00597004661 RX-86 Non-nucleoside reverse transcriptase inhibitors 00597004661 RX-86 Non-nucleoside reverse transcriptase inhibitors 333500410 RX-86 Non-nucleoside reverse transcriptase inhibitors 333500440 RX-86 Non-nucleoside reverse transcriptase inhibitors	RX-83	Nelfinavir 630100010	030
RX-83 Netfinavir 63010002770 RX-83 Netfinavir 68030728401 Rx-60 set Rx-code set Rx-code set Rx-code set Rx-code set Rx-code set Rx-84 Non-nucleoside reverse transcriptase inhibitors 00009376103 RX-86 Non-nucleoside reverse transcriptase inhibitors 00054464721 RX-86 Non-nucleoside reverse transcriptase inhibitors 00054646725 RX-86 Non-nucleoside reverse transcriptase inhibitors 00054664725 RX-86 Non-nucleoside reverse transcriptase inhibitors 00056047300 RX-86 Non-nucleoside reverse transcriptase inhibitors 00056047492 RX-86 Non-nucleoside reverse transcriptase inhibitors 0056051030 RX-86 Non-nucleoside reverse transcriptase inhibitors 00597004661 RX-86 Non-nucleoside reverse transcriptase inhibitors 00597004661 RX-86 Non-nucleoside reverse transcriptase inhibitors 00597004661 RX-86 Non-nucleoside reverse transcriptase inhibitors 333500410 RX-86 Non-nucleoside reverse transcriptase inhibitors 333500440 RX-86 Non-nucleoside reverse transcriptase inhibitors	RX-83	Nelfinavir 63010001	190
RX-83Nelfinavir66030728401Rx code set. Rx code set descriptionndcRX-86Non-nucleoside reverse transcriptase inhibitors00009376103RX-86Non-nucleoside reverse transcriptase inhibitors00054390558RX-86Non-nucleoside reverse transcriptase inhibitors00054464721RX-86Non-nucleoside reverse transcriptase inhibitors000564464725RX-86Non-nucleoside reverse transcriptase inhibitors00056047030RX-86Non-nucleoside reverse transcriptase inhibitors00056047300RX-86Non-nucleoside reverse transcriptase inhibitors00056047300RX-86Non-nucleoside reverse transcriptase inhibitors00056047300RX-86Non-nucleoside reverse transcriptase inhibitors00056047492RX-86Non-nucleoside reverse transcriptase inhibitors0057004601RX-86Non-nucleoside reverse transcriptase inhibitors00597004661RX-86Non-nucleoside reverse transcriptase inhibitors0597004661RX-86Non-nucleoside reverse transcriptase inhibitors3536006406RX-86Non-nucleoside reverse transcriptase inhibitors3536006406RX-86Non-nucleoside reverse transcriptase inhibitors35356007160RX-86Non-nucleoside reverse transcriptase inhibitors35356007160RX-86Non-nucleoside reverse transcriptase inhibitors35356007160RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleo			
Rx code set. Rx code set descriptionndcRX-86Non-nucleoside reverse transcriptase inhibitors00009376103RX-86Non-nucleoside reverse transcriptase inhibitors00054300558RX-86Non-nucleoside reverse transcriptase inhibitors00054464725RX-86Non-nucleoside reverse transcriptase inhibitors00054464725RX-86Non-nucleoside reverse transcriptase inhibitors00056047030RX-86Non-nucleoside reverse transcriptase inhibitors00056047030RX-86Non-nucleoside reverse transcriptase inhibitors00056047030RX-86Non-nucleoside reverse transcriptase inhibitors00550047030RX-86Non-nucleoside reverse transcriptase inhibitors00597004601RX-86Non-nucleoside reverse transcriptase inhibitors00597004601RX-86Non-nucleoside reverse transcriptase inhibitors00597004601RX-86Non-nucleoside reverse transcriptase inhibitors0597004661RX-86Non-nucleoside reverse transcriptase inhibitors15584010101RX-86Non-nucleoside reverse transcriptase inhibitors35356006406RX-86Non-nucleoside reverse transcriptase inhibitors35356007160RX-86Non-nucleoside reverse transcriptase inhibitors35356007160RX-86Non-nucleoside reverse transcriptase inhibitors35356007160RX-86Non-nucleoside reverse transcriptase inhibitors35356007160RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569456100 <td>RX-83</td> <td></td> <td></td>	RX-83		
RX-86Non-nucleoside reverse transcriptase inhibitors0009376103RX-86Non-nucleoside reverse transcriptase inhibitors00054390558RX-86Non-nucleoside reverse transcriptase inhibitors00054464725RX-86Non-nucleoside reverse transcriptase inhibitors00054464725RX-86Non-nucleoside reverse transcriptase inhibitors00056047030RX-86Non-nucleoside reverse transcriptase inhibitors00056047030RX-86Non-nucleoside reverse transcriptase inhibitors0005604730RX-86Non-nucleoside reverse transcriptase inhibitors00056047492RX-86Non-nucleoside reverse transcriptase inhibitors0057004601RX-86Non-nucleoside reverse transcriptase inhibitors0057004601RX-86Non-nucleoside reverse transcriptase inhibitors0057004701RX-86Non-nucleoside reverse transcriptase inhibitors0597004661RX-86Non-nucleoside reverse transcriptase inhibitors0597004724RX-86Non-nucleoside reverse transcriptase inhibitors35356006406RX-86Non-nucleoside reverse transcriptase inhibitors35356007106RX-86Non-nucleoside reverse transcriptase inhibitors35356007160RX-86Non-nucleoside reverse transcriptase inhibitors35356007160RX-86Non-nucleoside reverse transcriptase inhibitors3535601150RX-86Non-nucleoside reverse transcriptase inhibitors35456456101RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibit			
RX-86Non-nucleoside reverse transcriptase inhibitors00009737601RX-86Non-nucleoside reverse transcriptase inhibitors00054464721RX-86Non-nucleoside reverse transcriptase inhibitors00054464725RX-86Non-nucleoside reverse transcriptase inhibitors0005647300RX-86Non-nucleoside reverse transcriptase inhibitors00056047300RX-86Non-nucleoside reverse transcriptase inhibitors00056047300RX-86Non-nucleoside reverse transcriptase inhibitors00056047492RX-86Non-nucleoside reverse transcriptase inhibitors00057004601RX-86Non-nucleoside reverse transcriptase inhibitors00957004601RX-86Non-nucleoside reverse transcriptase inhibitors00957004601RX-86Non-nucleoside reverse transcriptase inhibitors00597004601RX-86Non-nucleoside reverse transcriptase inhibitors00597004601RX-86Non-nucleoside reverse transcriptase inhibitors0595700460RX-86Non-nucleoside reverse transcriptase inhibitors35356006406RX-86Non-nucleoside reverse transcriptase inhibitors35356007160RX-86Non-nucleoside reverse transcriptase inhibitors35356007224RX-86Non-nucleoside reverse transcriptase inhibitors3535600724RX-86Non-nucleoside reverse transcriptase inhibitors54569456101RX-86Non-nucleoside reverse transcriptase inhibitors54569456101RX-86Non-nucleoside reverse transcriptase inhibitors54569456101RX-86Non-nucleoside reverse transcriptase in			
RX-86Non-nucleoside reverse transcriptase inhibitors00054300588RX-86Non-nucleoside reverse transcriptase inhibitors00054464721RX-86Non-nucleoside reverse transcriptase inhibitors00054464725RX-86Non-nucleoside reverse transcriptase inhibitors00056047300RX-86Non-nucleoside reverse transcriptase inhibitors00056047300RX-86Non-nucleoside reverse transcriptase inhibitors0005604702RX-86Non-nucleoside reverse transcriptase inhibitors00056051030RX-86Non-nucleoside reverse transcriptase inhibitors00597004600RX-86Non-nucleoside reverse transcriptase inhibitors00597004600RX-86Non-nucleoside reverse transcriptase inhibitors00597004600RX-86Non-nucleoside reverse transcriptase inhibitors3535600406RX-86Non-nucleoside reverse transcriptase inhibitors3535600430RX-86Non-nucleoside reverse transcriptase inhibitors35356007160RX-86Non-nucleoside reverse transcriptase inhibitors35356007160RX-86Non-nucleoside reverse transcriptase inhibitors35356017160RX-86Non-nucleoside reverse transcriptase inhibitors35356011530RX-86Non-nucleoside reverse transcriptase inhibitors3535601760RX-86Non-nucleoside reverse transcriptase inhibitors3535601760RX-86Non-nucleoside reverse transcriptase inhibitors3535601760RX-86Non-nucleoside reverse transcriptase inhibitors3535601760RX-86Non-nucleoside reverse transcriptase inhibi	RX-86	Non-nucleoside reverse transcriptase inhibitors	
RX-86Non-nucleoside reverse transcriptase inhibitors00054464725RX-86Non-nucleoside reverse transcriptase inhibitors00054864725RX-86Non-nucleoside reverse transcriptase inhibitors0005604730RX-86Non-nucleoside reverse transcriptase inhibitors0005604730RX-86Non-nucleoside reverse transcriptase inhibitors00056047492RX-86Non-nucleoside reverse transcriptase inhibitors00056047492RX-86Non-nucleoside reverse transcriptase inhibitors00056051030RX-86Non-nucleoside reverse transcriptase inhibitors00597004601RX-86Non-nucleoside reverse transcriptase inhibitors00597004601RX-86Non-nucleoside reverse transcriptase inhibitors0597004601RX-86Non-nucleoside reverse transcriptase inhibitors35356006430RX-86Non-nucleoside reverse transcriptase inhibitors35356006430RX-86Non-nucleoside reverse transcriptase inhibitors35356007160RX-86Non-nucleoside reverse transcriptase inhibitors3535600724RX-86Non-nucleoside reverse transcriptase inhibitors3535601150RX-86Non-nucleoside reverse transcriptase inhibitors3535601150RX-86Non-nucleoside reverse transcriptase inhibitors3535601150RX-86Non-nucleoside reverse transcriptase inhibitors35469456101RX-86Non-nucleoside reverse transcriptase inhibitors54569456101RX-86Non-nucleoside reverse transcriptase inhibitors54569456101RX-86Non-nucleoside reverse transcriptase inhibi		Non-nucleoside reverse transcriptase inhibitors	00009757601
82%66Non-nucleoside reverse transcriptase inhibitors0005446472582%66Non-nucleoside reverse transcriptase inhibitors0005604703082%66Non-nucleoside reverse transcriptase inhibitors0005604703082%66Non-nucleoside reverse transcriptase inhibitors0005604749282%66Non-nucleoside reverse transcriptase inhibitors0005604749282%66Non-nucleoside reverse transcriptase inhibitors0005604749282%66Non-nucleoside reverse transcriptase inhibitors0095700460182%66Non-nucleoside reverse transcriptase inhibitors0095700460182%66Non-nucleoside reverse transcriptase inhibitors0059700466082%66Non-nucleoside reverse transcriptase inhibitors055860040682%66Non-nucleoside reverse transcriptase inhibitors3535600640682%66Non-nucleoside reverse transcriptase inhibitors3535600716082%66Non-nucleoside reverse transcriptase inhibitors3535600716082%66Non-nucleoside reverse transcriptase inhibitors3535600716082%66Non-nucleoside reverse transcriptase inhibitors3535601153082%66Non-nucleoside reverse transcriptase inhibitors3535601153082%66Non-nucleoside reverse transcriptase inhibitors3535601150682%66Non-nucleoside reverse transcriptase inhibitors35456945610082%66Non-nucleoside reverse transcriptase inhibitors5456945610082%66Non-nucleoside reverse transcriptase inhibitors545695620082%66Non-nucleoside reverse transcriptase		Non-nucleoside reverse transcriptase inhibitors	00054390558
8X-86Non-nucleoside reverse transcriptase inhibitors000560470308X-86Non-nucleoside reverse transcriptase inhibitors000560473308X-86Non-nucleoside reverse transcriptase inhibitors000560474928X-86Non-nucleoside reverse transcriptase inhibitors000560170308X-86Non-nucleoside reverse transcriptase inhibitors000560170308X-86Non-nucleoside reverse transcriptase inhibitors005970046618X-86Non-nucleoside reverse transcriptase inhibitors005970046618X-86Non-nucleoside reverse transcriptase inhibitors005970046618X-86Non-nucleoside reverse transcriptase inhibitors353560064068X-86Non-nucleoside reverse transcriptase inhibitors353560064068X-86Non-nucleoside reverse transcriptase inhibitors353560071068X-86Non-nucleoside reverse transcriptase inhibitors353560072248X-86Non-nucleoside reverse transcriptase inhibitors353560172248X-86Non-nucleoside reverse transcriptase inhibitors35356017068X-86Non-nucleoside reverse transcriptase inhibitors35356017068X-86Non-nucleoside reverse transcriptase inhibitors35356017068X-86Non-nucleoside reverse transcriptase inhibitors35356017068X-86Non-nucleoside reverse transcriptase inhibitors354569451018X-86Non-nucleoside reverse transcriptase inhibitors54569451018X-86Non-nucleoside reverse transcriptase inhibitors54569451008X-86Non-nucleoside reverse transcriptase inhib	RX-86	Non-nucleoside reverse transcriptase inhibitors	00054464721
82×86Non-nucleoside reverse transcriptase inhibitors0005604703082×86Non-nucleoside reverse transcriptase inhibitors0005604739082×86Non-nucleoside reverse transcriptase inhibitors0005605103082×86Non-nucleoside reverse transcriptase inhibitors0059700460182×86Non-nucleoside reverse transcriptase inhibitors0059700460182×86Non-nucleoside reverse transcriptase inhibitors0059700460182×86Non-nucleoside reverse transcriptase inhibitors005970046182×86Non-nucleoside reverse transcriptase inhibitors005970046182×86Non-nucleoside reverse transcriptase inhibitors353560040682×86Non-nucleoside reverse transcriptase inhibitors353560044082×86Non-nucleoside reverse transcriptase inhibitors3535600710682×86Non-nucleoside reverse transcriptase inhibitors3535600716082×86Non-nucleoside reverse transcriptase inhibitors3535600716082×86Non-nucleoside reverse transcriptase inhibitors3535600716082×86Non-nucleoside reverse transcriptase inhibitors3535601150682×86Non-nucleoside reverse transcriptase inhibitors35456945610182×86Non-nucleoside reverse transcriptase inhibitors5456945610182×86Non-nucleoside reverse transcriptase inhibitors5456945610182×86Non-nucleoside reverse transcriptase inhibitors5456945610082×86Non-nucleoside reverse transcriptase inhibitors5456945610082×86Non-nucleoside reverse transcriptase in	RX-86	Non-nucleoside reverse transcriptase inhibitors	00054464725
8X-86Non-nucleoside reverse transcriptase inhibitors000560473308X-86Non-nucleoside reverse transcriptase inhibitors000560474928X-86Non-nucleoside reverse transcriptase inhibitors005970046018X-86Non-nucleoside reverse transcriptase inhibitors005970046608X-86Non-nucleoside reverse transcriptase inhibitors005970046608X-86Non-nucleoside reverse transcriptase inhibitors005970046608X-86Non-nucleoside reverse transcriptase inhibitors35356004068X-86Non-nucleoside reverse transcriptase inhibitors35356004308X-86Non-nucleoside reverse transcriptase inhibitors35356004308X-86Non-nucleoside reverse transcriptase inhibitors353560071608X-86Non-nucleoside reverse transcriptase inhibitors353560071608X-86Non-nucleoside reverse transcriptase inhibitors35356011568X-86Non-nucleoside reverse transcriptase inhibitors35356011508X-86Non-nucleoside reverse transcriptase inhibitors353560115308X-86Non-nucleoside reverse transcriptase inhibitors545694561018X-86Non-nucleoside reverse transcriptase inhibitors545694561018X-86Non-nucleoside reverse transcriptase inhibitors545694561018X-86Non-nucleoside reverse transcriptase inhibitors54569451008X-86Non-nucleoside reverse transcriptase inhibitors54569451008X-86Non-nucleoside reverse transcriptase inhibitors54569451008X-86Non-nucleoside reverse transcriptase inhibit	RX-86	Non-nucleoside reverse transcriptase inhibitors	00054864725
RX-86Non-nucleoside reverse transcriptase inhibitors00056051030RX-86Non-nucleoside reverse transcriptase inhibitors00597004601RX-86Non-nucleoside reverse transcriptase inhibitors00597004601RX-86Non-nucleoside reverse transcriptase inhibitors00597004601RX-86Non-nucleoside reverse transcriptase inhibitors00597004724RX-86Non-nucleoside reverse transcriptase inhibitors15584010101RX-86Non-nucleoside reverse transcriptase inhibitors35356006406RX-86Non-nucleoside reverse transcriptase inhibitors35356006430RX-86Non-nucleoside reverse transcriptase inhibitors35356007106RX-86Non-nucleoside reverse transcriptase inhibitors35356007106RX-86Non-nucleoside reverse transcriptase inhibitors35356007106RX-86Non-nucleoside reverse transcriptase inhibitors35356007106RX-86Non-nucleoside reverse transcriptase inhibitors35356011506RX-86Non-nucleoside reverse transcriptase inhibitors35356011506RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase		Non-nucleoside reverse transcriptase inhibitors	00056047030
8X-86Non-nucleoside reverse transcriptase inhibitors000500510308X-86Non-nucleoside reverse transcriptase inhibitors005970046018X-86Non-nucleoside reverse transcriptase inhibitors005970046018X-86Non-nucleoside reverse transcriptase inhibitors005970046018X-86Non-nucleoside reverse transcriptase inhibitors155840101018X-86Non-nucleoside reverse transcriptase inhibitors353560064308X-86Non-nucleoside reverse transcriptase inhibitors353560064308X-86Non-nucleoside reverse transcriptase inhibitors353560071608X-86Non-nucleoside reverse transcriptase inhibitors353560071608X-86Non-nucleoside reverse transcriptase inhibitors353560071608X-86Non-nucleoside reverse transcriptase inhibitors35356015308X-86Non-nucleoside reverse transcriptase inhibitors35356015308X-86Non-nucleoside reverse transcriptase inhibitors35356015308X-86Non-nucleoside reverse transcriptase inhibitors545694561008X-86Non-nucleoside reverse transcriptase inhibitors54569502008X-86Non-nucleoside reverse transcriptase inh	RX-86	Non-nucleoside reverse transcriptase inhibitors	00056047330
8X-86Non-nucleoside reverse transcriptase inhibitors005970046018X-86Non-nucleoside reverse transcriptase inhibitors005970046018X-86Non-nucleoside reverse transcriptase inhibitors005970046018X-86Non-nucleoside reverse transcriptase inhibitors155840101018X-86Non-nucleoside reverse transcriptase inhibitors353360064068X-86Non-nucleoside reverse transcriptase inhibitors353360064068X-86Non-nucleoside reverse transcriptase inhibitors353360064068X-86Non-nucleoside reverse transcriptase inhibitors353360071068X-86Non-nucleoside reverse transcriptase inhibitors353360071068X-86Non-nucleoside reverse transcriptase inhibitors353360071248X-86Non-nucleoside reverse transcriptase inhibitors353560115068X-86Non-nucleoside reverse transcriptase inhibitors353560115068X-86Non-nucleoside reverse transcriptase inhibitors545694561008X-86Non-nucleoside reverse transcriptase inhibitors545694561008X-86Non-nucleoside reverse transcriptase inhibitors545694561008X-86Non-nucleoside reverse transcriptase inhibitors545695602008X-86Non-nucleoside reverse transcriptase inhibitors545695602008X-86Non-nucleoside reverse transcriptase inhibitors5486883844018X-86Non-nucleoside reverse transcriptase inhibitors548688864008X-86Non-nucleoside reverse transcriptase inhibitors5486886468008X-86Non-nucleoside reverse transcripta	RX-86	Non-nucleoside reverse transcriptase inhibitors	00056047492
RX-86Non-nucleoside reverse transcriptase inhibitors00597004660RX-86Non-nucleoside reverse transcriptase inhibitors00597004724RX-86Non-nucleoside reverse transcriptase inhibitors15584010101RX-86Non-nucleoside reverse transcriptase inhibitors33356006430RX-86Non-nucleoside reverse transcriptase inhibitors33356006430RX-86Non-nucleoside reverse transcriptase inhibitors33356007100RX-86Non-nucleoside reverse transcriptase inhibitors33356007100RX-86Non-nucleoside reverse transcriptase inhibitors33356007160RX-86Non-nucleoside reverse transcriptase inhibitors33356007160RX-86Non-nucleoside reverse transcriptase inhibitors33356007160RX-86Non-nucleoside reverse transcriptase inhibitors33356011506RX-86Non-nucleoside reverse transcriptase inhibitors33356011500RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569512200RX-86Non-nucleoside reverse transcriptase inhibitors545695037400RX-86Non-nucleoside reverse transcriptase inhibitors54569560200RX-86Non-nucleoside reverse transcriptase inhibitors54569560200RX-86Non-nucleoside reverse transcriptase inhibitors54569560200RX-86Non-nucleoside reverse transcriptase inhibitors5456950200RX-86Non-nucleoside reverse transcriptase	RX-86	Non-nucleoside reverse transcriptase inhibitors	00056051030
RX-86Non-nucleoside reverse transcriptase inhibitors00597004660RX-86Non-nucleoside reverse transcriptase inhibitors00597004724RX-86Non-nucleoside reverse transcriptase inhibitors15584010101RX-86Non-nucleoside reverse transcriptase inhibitors35356006430RX-86Non-nucleoside reverse transcriptase inhibitors35356006430RX-86Non-nucleoside reverse transcriptase inhibitors35356007106RX-86Non-nucleoside reverse transcriptase inhibitors35356007106RX-86Non-nucleoside reverse transcriptase inhibitors35356007160RX-86Non-nucleoside reverse transcriptase inhibitors35356007160RX-86Non-nucleoside reverse transcriptase inhibitors3535601506RX-86Non-nucleoside reverse transcriptase inhibitors35356011506RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569512200RX-86Non-nucleoside reverse transcriptase inhibitors54569550200RX-86Non-nucleoside reverse transcriptase inhibitors54569550200RX-86Non-nucleoside reverse transcriptase inhibitors54569550200RX-86Non-nucleoside reverse transcriptase inhibitors5456950200RX-86Non-nucleoside reverse transcriptase inhibitors5456950200RX-86Non-nucleoside reverse transcriptase in	RX-86	Non-nucleoside reverse transcriptase inhibitors	00597004601
RX-86Non-nucleoside reverse transcriptase inhibitors00597004661RX-86Non-nucleoside reverse transcriptase inhibitors15584010101RX-86Non-nucleoside reverse transcriptase inhibitors35356006406RX-86Non-nucleoside reverse transcriptase inhibitors35356006406RX-86Non-nucleoside reverse transcriptase inhibitors35356006990RX-86Non-nucleoside reverse transcriptase inhibitors35356007106RX-86Non-nucleoside reverse transcriptase inhibitors35356007224RX-86Non-nucleoside reverse transcriptase inhibitors35356007224RX-86Non-nucleoside reverse transcriptase inhibitors35356011506RX-86Non-nucleoside reverse transcriptase inhibitors35356011506RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors5456950200RX-86Non-nucleoside reverse transcriptase inhibitors5456950200RX-86Non-nucleoside reverse transcriptase inhibitors54868384400RX-86Non-nucleoside reverse transcriptase inhibitors54868384401RX-86Non-nucleoside reverse transcriptase inhibitors54868384401RX-86Non-nucleoside reverse transcriptase inhibitors5486384400RX-86Non-nucleoside reverse transcriptase in	RX-86		00597004660
RX-86Non-nucleoside reverse transcriptase inhibitors00597004724RX-86Non-nucleoside reverse transcriptase inhibitors15584010101RX-86Non-nucleoside reverse transcriptase inhibitors35356006406RX-86Non-nucleoside reverse transcriptase inhibitors35356007106RX-86Non-nucleoside reverse transcriptase inhibitors35356007106RX-86Non-nucleoside reverse transcriptase inhibitors35356007160RX-86Non-nucleoside reverse transcriptase inhibitors35356011506RX-86Non-nucleoside reverse transcriptase inhibitors35356011506RX-86Non-nucleoside reverse transcriptase inhibitors35356011506RX-86Non-nucleoside reverse transcriptase inhibitors35356011500RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569571200RX-86Non-nucleoside reverse transcriptase inhibitors5456950500RX-86Non-nucleoside reverse transcriptase inhibitors5466384400RX-86Non-nucleoside reverse transcriptase inhibitors54868384400RX-86Non-nucleoside reverse transcriptase inhibitors54868452000RX-86Non-nucleoside reverse transcriptase inhibitors54868452000RX-86Non-nucleoside reverse transcriptase inhibitors54869580500RX-86Non-nucleoside reverse transcriptase i	RX-86		00597004661
RX-86Non-nucleoside reverse transcriptase inhibitors35356006406RX-86Non-nucleoside reverse transcriptase inhibitors35356006430RX-86Non-nucleoside reverse transcriptase inhibitors35356006990RX-86Non-nucleoside reverse transcriptase inhibitors35356007106RX-86Non-nucleoside reverse transcriptase inhibitors35356007160RX-86Non-nucleoside reverse transcriptase inhibitors35356007224RX-86Non-nucleoside reverse transcriptase inhibitors35356011506RX-86Non-nucleoside reverse transcriptase inhibitors35356011506RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569456200RX-86Non-nucleoside reverse transcriptase inhibitors54569512200RX-86Non-nucleoside reverse transcriptase inhibitors545695000RX-86Non-nucleoside reverse transcriptase inhibitors545695000RX-86Non-nucleoside reverse transcriptase inhibitors54668384400RX-86Non-nucleoside reverse transcriptase inhibitors54868384400RX-86Non-nucleoside reverse transcriptase inhibitors54868384400RX-86Non-nucleoside reverse transcriptase inhibitors54868384400RX-86Non-nucleoside reverse transcriptase inhibitors54868386400RX-86Non-nucleoside reverse transcriptase inhibitors54868386400RX-86Non-nucleoside reverse transcriptase inh	RX-86	Non-nucleoside reverse transcriptase inhibitors	00597004724
RX-86Non-nucleoside reverse transcriptase inhibitors35356006430RX-86Non-nucleoside reverse transcriptase inhibitors35356007106RX-86Non-nucleoside reverse transcriptase inhibitors35356007160RX-86Non-nucleoside reverse transcriptase inhibitors35356007224RX-86Non-nucleoside reverse transcriptase inhibitors35356011506RX-86Non-nucleoside reverse transcriptase inhibitors35356011506RX-86Non-nucleoside reverse transcriptase inhibitors35356011506RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569456101RX-86Non-nucleoside reverse transcriptase inhibitors54569456200RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569450200RX-86Non-nucleoside reverse transcriptase inhibitors5456950200RX-86Non-nucleoside reverse transcriptase inhibitors5456950200RX-86Non-nucleoside reverse transcriptase inhibitors5456950200RX-86Non-nucleoside reverse transcriptase inhibitors54868384400RX-86Non-nucleoside reverse transcriptase inhibitors54868384400RX-86Non-nucleoside reverse transcriptase inhibitors54868452000RX-86Non-nucleoside reverse transcriptase inhibitors548684586400RX-86Non-nucleoside reverse transcriptase inhibitors54868386400RX-86Non-nucleoside reverse transcriptase i	RX-86	Non-nucleoside reverse transcriptase inhibitors	15584010101
RX-86Non-nucleoside reverse transcriptase inhibitors35356006430RX-86Non-nucleoside reverse transcriptase inhibitors35356007106RX-86Non-nucleoside reverse transcriptase inhibitors35356007160RX-86Non-nucleoside reverse transcriptase inhibitors35356007224RX-86Non-nucleoside reverse transcriptase inhibitors35356017160RX-86Non-nucleoside reverse transcriptase inhibitors35356011506RX-86Non-nucleoside reverse transcriptase inhibitors35356011530RX-86Non-nucleoside reverse transcriptase inhibitors54569456101RX-86Non-nucleoside reverse transcriptase inhibitors54569456101RX-86Non-nucleoside reverse transcriptase inhibitors54569456200RX-86Non-nucleoside reverse transcriptase inhibitors54569450200RX-86Non-nucleoside reverse transcriptase inhibitors5456950200RX-86Non-nucleoside reverse transcriptase inhibitors5456950200RX-86Non-nucleoside reverse transcriptase inhibitors5456950200RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569560200RX-86Non-nucleoside reverse transcriptase in	RX-86		35356006406
RX-86Non-nucleoside reverse transcriptase inhibitors35356006990RX-86Non-nucleoside reverse transcriptase inhibitors35356007160RX-86Non-nucleoside reverse transcriptase inhibitors35356007224RX-86Non-nucleoside reverse transcriptase inhibitors35356011506RX-86Non-nucleoside reverse transcriptase inhibitors35356011530RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569456200RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569456200RX-86Non-nucleoside reverse transcriptase inhibitors54569501200RX-86Non-nucleoside reverse transcriptase inhibitors545695000RX-86Non-nucleoside reverse transcriptase inhibitors54688384400RX-86Non-nucleoside reverse transcriptase inhibitors54868384400RX-86Non-nucleoside reverse transcriptase inhibitors54868466800RX-86Non-nucleoside reverse transcriptase inhibitors54868466800RX-86Non-nucleoside reverse transcriptase inhibitors54868466800RX-86Non-nucleoside reverse transcriptase inhibitors54868586400RX-86Non-nucleoside reverse transcriptase inhibitors55289039203RX-86Non-nucleoside reverse transcriptase i	RX-86		35356006430
RX-86Non-nucleoside reverse transcriptase inhibitors35356007106RX-86Non-nucleoside reverse transcriptase inhibitors35356007124RX-86Non-nucleoside reverse transcriptase inhibitors35356011506RX-86Non-nucleoside reverse transcriptase inhibitors35356011506RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569456101RX-86Non-nucleoside reverse transcriptase inhibitors54569456200RX-86Non-nucleoside reverse transcriptase inhibitors54569456101RX-86Non-nucleoside reverse transcriptase inhibitors54569512200RX-86Non-nucleoside reverse transcriptase inhibitors54569512200RX-86Non-nucleoside reverse transcriptase inhibitors5456950200RX-86Non-nucleoside reverse transcriptase inhibitors54569560200RX-86Non-nucleoside reverse transcriptase inhibitors54868384400RX-86Non-nucleoside reverse transcriptase inhibitors54868452000RX-86Non-nucleoside reverse transcriptase inhibitors54868452000RX-86Non-nucleoside reverse transcriptase inhibitors54868452000RX-86Non-nucleoside reverse transcriptase inhibitors54868384401RX-86Non-nucleoside reverse transcriptase inhibitors54868384401RX-86Non-nucleoside reverse transcriptase inhibitors54868386400RX-86Non-nucleoside reverse transcriptase inhibitors54868386400RX-86Non-nucleoside reverse transcriptase	RX-86		35356006990
RX-86Non-nucleoside reverse transcriptase inhibitors35356007214RX-86Non-nucleoside reverse transcriptase inhibitors35356007224RX-86Non-nucleoside reverse transcriptase inhibitors35356011506RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569456101RX-86Non-nucleoside reverse transcriptase inhibitors54569456200RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569456200RX-86Non-nucleoside reverse transcriptase inhibitors54569512200RX-86Non-nucleoside reverse transcriptase inhibitors5456950200RX-86Non-nucleoside reverse transcriptase inhibitors5456950200RX-86Non-nucleoside reverse transcriptase inhibitors5456950200RX-86Non-nucleoside reverse transcriptase inhibitors5456950200RX-86Non-nucleoside reverse transcriptase inhibitors54868384400RX-86Non-nucleoside reverse transcriptase inhibitors5486846800RX-86Non-nucleoside reverse transcriptase inhibitors54868466800RX-86Non-nucleoside reverse transcriptase inhibitors55289039203RX-86Non-nucleoside reverse transcriptase inhibitors55289039203RX-86Non-nucleoside reverse transcriptase inhibitors63010002036RX-86Non-nucleoside reverse transcriptase inhibitors63010002036RX-86Non-nucleoside reverse transcriptase inhi	RX-86		35356007106
RX-86Non-nucleoside reverse transcriptase inhibitors35356007224RX-86Non-nucleoside reverse transcriptase inhibitors35356011506RX-86Non-nucleoside reverse transcriptase inhibitors35356011530RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569456101RX-86Non-nucleoside reverse transcriptase inhibitors54569456200RX-86Non-nucleoside reverse transcriptase inhibitors5456945100RX-86Non-nucleoside reverse transcriptase inhibitors54569512200RX-86Non-nucleoside reverse transcriptase inhibitors54569560200RX-86Non-nucleoside reverse transcriptase inhibitors54569580500RX-86Non-nucleoside reverse transcriptase inhibitors54868384400RX-86Non-nucleoside reverse transcriptase inhibitors548684842000RX-86Non-nucleoside reverse transcriptase inhibitors5486846800RX-86Non-nucleoside reverse transcriptase inhibitors5486846800RX-86Non-nucleoside reverse transcriptase inhibitors55289039203RX-86Non-nucleoside reverse transcriptase inhibitors55289039203RX-86Non-nucleoside reverse transcriptase inhibitors59676057001RX-86Non-nucleoside reverse transcriptase inhibitors63010002036RX-86Non-nucleoside reverse transcriptase inhibitors67263043460RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase i	RX-86		35356007160
RX-86Non-nucleoside reverse transcriptase inhibitors35356011530RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569456200RX-86Non-nucleoside reverse transcriptase inhibitors54569450200RX-86Non-nucleoside reverse transcriptase inhibitors54569451100RX-86Non-nucleoside reverse transcriptase inhibitors54569461100RX-86Non-nucleoside reverse transcriptase inhibitors5456950200RX-86Non-nucleoside reverse transcriptase inhibitors5456950200RX-86Non-nucleoside reverse transcriptase inhibitors54569580500RX-86Non-nucleoside reverse transcriptase inhibitors54669580500RX-86Non-nucleoside reverse transcriptase inhibitors54868384401RX-86Non-nucleoside reverse transcriptase inhibitors5486486800RX-86Non-nucleoside reverse transcriptase inhibitors5486486800RX-86Non-nucleoside reverse transcriptase inhibitors5486846800RX-86Non-nucleoside reverse transcriptase inhibitors55289039203RX-86Non-nucleoside reverse transcriptase inhibitors55289039203RX-86Non-nucleoside reverse transcriptase inhibitors63010002036RX-86Non-nucleoside reverse transcriptase inhibitors63010002036RX-86Non-nucleoside reverse transcriptase inhibitors63201002036RX-86Non-nucleoside reverse transcriptase inhibitors6320043836RX-86Non-nucleoside reverse transcriptase inhib	RX-86	Non-nucleoside reverse transcriptase inhibitors	35356007224
RX-86Non-nucleoside reverse transcriptase inhibitors54569456100RX-86Non-nucleoside reverse transcriptase inhibitors54569456101RX-86Non-nucleoside reverse transcriptase inhibitors54569456200RX-86Non-nucleoside reverse transcriptase inhibitors54569456200RX-86Non-nucleoside reverse transcriptase inhibitors54569512200RX-86Non-nucleoside reverse transcriptase inhibitors54569512200RX-86Non-nucleoside reverse transcriptase inhibitors5456950200RX-86Non-nucleoside reverse transcriptase inhibitors54569580500RX-86Non-nucleoside reverse transcriptase inhibitors54868384400RX-86Non-nucleoside reverse transcriptase inhibitors54868452000RX-86Non-nucleoside reverse transcriptase inhibitors5528039203RX-86Non-nucleoside reverse transcriptase inhibitors55289039203RX-86Non-nucleoside reverse transcriptase inhibitors63010002036RX-86Non-nucleoside reverse transcriptase inhibitors63010002036RX-86Non-nucleoside reverse transcriptase inhibitors67263043460RX-86Non-nucleoside reverse transcriptase inhibitors67263043836RX-86Non-nucleoside reverse transcriptase i	RX-86	Non-nucleoside reverse transcriptase inhibitors	35356011506
RX-86Non-nucleoside reverse transcriptase inhibitors54569456101RX-86Non-nucleoside reverse transcriptase inhibitors54569461100RX-86Non-nucleoside reverse transcriptase inhibitors54569461100RX-86Non-nucleoside reverse transcriptase inhibitors54569512200RX-86Non-nucleoside reverse transcriptase inhibitors54569537400RX-86Non-nucleoside reverse transcriptase inhibitors54569560200RX-86Non-nucleoside reverse transcriptase inhibitors54569580500RX-86Non-nucleoside reverse transcriptase inhibitors54868384401RX-86Non-nucleoside reverse transcriptase inhibitors548684884401RX-86Non-nucleoside reverse transcriptase inhibitors5486848600RX-86Non-nucleoside reverse transcriptase inhibitors5486846600RX-86Non-nucleoside reverse transcriptase inhibitors54868466800RX-86Non-nucleoside reverse transcriptase inhibitors5289039203RX-86Non-nucleoside reverse transcriptase inhibitors55289039203RX-86Non-nucleoside reverse transcriptase inhibitors5067057001RX-86Non-nucleoside reverse transcriptase inhibitors63010002036RX-86Non-nucleoside reverse transcriptase inhibitors67263043460RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase in	RX-86	Non-nucleoside reverse transcriptase inhibitors	35356011530
RX-86Non-nucleoside reverse transcriptase inhibitors54569456200RX-86Non-nucleoside reverse transcriptase inhibitors54569461100RX-86Non-nucleoside reverse transcriptase inhibitors54569512200RX-86Non-nucleoside reverse transcriptase inhibitors5456957400RX-86Non-nucleoside reverse transcriptase inhibitors545695000RX-86Non-nucleoside reverse transcriptase inhibitors54680500RX-86Non-nucleoside reverse transcriptase inhibitors54868384400RX-86Non-nucleoside reverse transcriptase inhibitors54868384400RX-86Non-nucleoside reverse transcriptase inhibitors54868384400RX-86Non-nucleoside reverse transcriptase inhibitors54868452000RX-86Non-nucleoside reverse transcriptase inhibitors5486846800RX-86Non-nucleoside reverse transcriptase inhibitors5486846800RX-86Non-nucleoside reverse transcriptase inhibitors55289039203RX-86Non-nucleoside reverse transcriptase inhibitors55289039203RX-86Non-nucleoside reverse transcriptase inhibitors63010002036RX-86Non-nucleoside reverse transcriptase inhibitors63010002036RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase inhibit	RX-86	Non-nucleoside reverse transcriptase inhibitors	54569456100
RX-86Non-nucleoside reverse transcriptase inhibitors54569461100RX-86Non-nucleoside reverse transcriptase inhibitors54569512200RX-86Non-nucleoside reverse transcriptase inhibitors5456950200RX-86Non-nucleoside reverse transcriptase inhibitors54569560200RX-86Non-nucleoside reverse transcriptase inhibitors54569580500RX-86Non-nucleoside reverse transcriptase inhibitors54868384400RX-86Non-nucleoside reverse transcriptase inhibitors54868384401RX-86Non-nucleoside reverse transcriptase inhibitors54868452000RX-86Non-nucleoside reverse transcriptase inhibitors54868466800RX-86Non-nucleoside reverse transcriptase inhibitors54868466800RX-86Non-nucleoside reverse transcriptase inhibitors55289039203RX-86Non-nucleoside reverse transcriptase inhibitors55289039263RX-86Non-nucleoside reverse transcriptase inhibitors59676057001RX-86Non-nucleoside reverse transcriptase inhibitors63010002036RX-86Non-nucleoside reverse transcriptase inhibitors67263043460RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase	RX-86	Non-nucleoside reverse transcriptase inhibitors	54569456101
RX-86Non-nucleoside reverse transcriptase inhibitors54569512200RX-86Non-nucleoside reverse transcriptase inhibitors54569537400RX-86Non-nucleoside reverse transcriptase inhibitors54569560200RX-86Non-nucleoside reverse transcriptase inhibitors54569580500RX-86Non-nucleoside reverse transcriptase inhibitors54868384400RX-86Non-nucleoside reverse transcriptase inhibitors54868384401RX-86Non-nucleoside reverse transcriptase inhibitors54868384401RX-86Non-nucleoside reverse transcriptase inhibitors54868466800RX-86Non-nucleoside reverse transcriptase inhibitors54868466800RX-86Non-nucleoside reverse transcriptase inhibitors55289039203RX-86Non-nucleoside reverse transcriptase inhibitors55289039203RX-86Non-nucleoside reverse transcriptase inhibitors55289039263RX-86Non-nucleoside reverse transcriptase inhibitors6301000236RX-86Non-nucleoside reverse transcriptase inhibitors6301000236RX-86Non-nucleoside reverse transcriptase inhibitors67263043460RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase i	RX-86	Non-nucleoside reverse transcriptase inhibitors	54569456200
RX-86Non-nucleoside reverse transcriptase inhibitors54569537400RX-86Non-nucleoside reverse transcriptase inhibitors54569560200RX-86Non-nucleoside reverse transcriptase inhibitors54569580500RX-86Non-nucleoside reverse transcriptase inhibitors54868384400RX-86Non-nucleoside reverse transcriptase inhibitors54868384401RX-86Non-nucleoside reverse transcriptase inhibitors54868384401RX-86Non-nucleoside reverse transcriptase inhibitors5486846800RX-86Non-nucleoside reverse transcriptase inhibitors5486886400RX-86Non-nucleoside reverse transcriptase inhibitors55289039203RX-86Non-nucleoside reverse transcriptase inhibitors55289039263RX-86Non-nucleoside reverse transcriptase inhibitors59676057001RX-86Non-nucleoside reverse transcriptase inhibitors63010002036RX-86Non-nucleoside reverse transcriptase inhibitors63010002118RX-86Non-nucleoside reverse transcriptase inhibitors67263043860RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase inhibitors68258902001RX-86Non-nucleoside reverse transcriptase i	RX-86	Non-nucleoside reverse transcriptase inhibitors	54569461100
RX-86Non-nucleoside reverse transcriptase inhibitors54569560200RX-86Non-nucleoside reverse transcriptase inhibitors54569580500RX-86Non-nucleoside reverse transcriptase inhibitors54868384400RX-86Non-nucleoside reverse transcriptase inhibitors54868384401RX-86Non-nucleoside reverse transcriptase inhibitors5486846800RX-86Non-nucleoside reverse transcriptase inhibitors54868466800RX-86Non-nucleoside reverse transcriptase inhibitors54868586400RX-86Non-nucleoside reverse transcriptase inhibitors55289039203RX-86Non-nucleoside reverse transcriptase inhibitors55289039263RX-86Non-nucleoside reverse transcriptase inhibitors59676057001RX-86Non-nucleoside reverse transcriptase inhibitors63010002036RX-86Non-nucleoside reverse transcriptase inhibitors67263043460RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase inhibitors68258902001RX-86Non-nucleoside reverse transcriptase inhibitors68258902001RX-86Non-nucleoside reverse transcriptase	RX-86	Non-nucleoside reverse transcriptase inhibitors	54569512200
RX-86Non-nucleoside reverse transcriptase inhibitors54569580500RX-86Non-nucleoside reverse transcriptase inhibitors54868384400RX-86Non-nucleoside reverse transcriptase inhibitors54868384401RX-86Non-nucleoside reverse transcriptase inhibitors54868452000RX-86Non-nucleoside reverse transcriptase inhibitors54868466800RX-86Non-nucleoside reverse transcriptase inhibitors54868586400RX-86Non-nucleoside reverse transcriptase inhibitors55289039203RX-86Non-nucleoside reverse transcriptase inhibitors55289039263RX-86Non-nucleoside reverse transcriptase inhibitors59676057001RX-86Non-nucleoside reverse transcriptase inhibitors63010002036RX-86Non-nucleoside reverse transcriptase inhibitors67263043460RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase inhibitors67263056830RX-86Non-nucleoside reverse transcriptase inhibitors67263056830RX-86Non-nucleoside reverse transcriptase inhibitors67263056830RX-86Non-nucleoside reverse transcriptase inhibitors68258902101RX-86Non-nucleoside reverse transcriptase inhibitors68258902101	RX-86	Non-nucleoside reverse transcriptase inhibitors	54569537400
RX-86Non-nucleoside reverse transcriptase inhibitors54868384400RX-86Non-nucleoside reverse transcriptase inhibitors54868384401RX-86Non-nucleoside reverse transcriptase inhibitors54868384401RX-86Non-nucleoside reverse transcriptase inhibitors5486846800RX-86Non-nucleoside reverse transcriptase inhibitors54868586400RX-86Non-nucleoside reverse transcriptase inhibitors55289039203RX-86Non-nucleoside reverse transcriptase inhibitors55289039263RX-86Non-nucleoside reverse transcriptase inhibitors59676057001RX-86Non-nucleoside reverse transcriptase inhibitors63010002036RX-86Non-nucleoside reverse transcriptase inhibitors63010002118RX-86Non-nucleoside reverse transcriptase inhibitors67263043460RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase inhibitors68258902001RX-86Non-nucleoside reverse transcriptase inhibitors68258902101	RX-86	Non-nucleoside reverse transcriptase inhibitors	54569560200
RX-86Non-nucleoside reverse transcriptase inhibitors54868384401RX-86Non-nucleoside reverse transcriptase inhibitors54868452000RX-86Non-nucleoside reverse transcriptase inhibitors54868466800RX-86Non-nucleoside reverse transcriptase inhibitors54868586400RX-86Non-nucleoside reverse transcriptase inhibitors55289039203RX-86Non-nucleoside reverse transcriptase inhibitors55289039263RX-86Non-nucleoside reverse transcriptase inhibitors59676057001RX-86Non-nucleoside reverse transcriptase inhibitors63010002036RX-86Non-nucleoside reverse transcriptase inhibitors63010002118RX-86Non-nucleoside reverse transcriptase inhibitors67263043460RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase inhibitors68258902001RX-86Non-nucleoside reverse transcriptase inhibitors68258902101	RX-86	Non-nucleoside reverse transcriptase inhibitors	54569580500
RX-86Non-nucleoside reverse transcriptase inhibitors54868452000RX-86Non-nucleoside reverse transcriptase inhibitors54868466800RX-86Non-nucleoside reverse transcriptase inhibitors54868586400RX-86Non-nucleoside reverse transcriptase inhibitors55289039203RX-86Non-nucleoside reverse transcriptase inhibitors55289039263RX-86Non-nucleoside reverse transcriptase inhibitors59676057001RX-86Non-nucleoside reverse transcriptase inhibitors63010002036RX-86Non-nucleoside reverse transcriptase inhibitors63010002118RX-86Non-nucleoside reverse transcriptase inhibitors67263043460RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase inhibitors67263056830RX-86Non-nucleoside reverse transcriptase inhibitors68258902001RX-86Non-nucleoside reverse transcriptase inhibitors68258902101	RX-86	Non-nucleoside reverse transcriptase inhibitors	54868384400
RX-86Non-nucleoside reverse transcriptase inhibitors54868466800RX-86Non-nucleoside reverse transcriptase inhibitors54868586400RX-86Non-nucleoside reverse transcriptase inhibitors55289039203RX-86Non-nucleoside reverse transcriptase inhibitors55289039263RX-86Non-nucleoside reverse transcriptase inhibitors59676057001RX-86Non-nucleoside reverse transcriptase inhibitors63010002036RX-86Non-nucleoside reverse transcriptase inhibitors63010002118RX-86Non-nucleoside reverse transcriptase inhibitors67263043460RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase inhibitors67263056830RX-86Non-nucleoside reverse transcriptase inhibitors67263056830RX-86Non-nucleoside reverse transcriptase inhibitors68258902001RX-86Non-nucleoside reverse transcriptase inhibitors68258902101	RX-86	Non-nucleoside reverse transcriptase inhibitors	54868384401
RX-86Non-nucleoside reverse transcriptase inhibitors54868586400RX-86Non-nucleoside reverse transcriptase inhibitors55289039203RX-86Non-nucleoside reverse transcriptase inhibitors55289039263RX-86Non-nucleoside reverse transcriptase inhibitors59676057001RX-86Non-nucleoside reverse transcriptase inhibitors63010002036RX-86Non-nucleoside reverse transcriptase inhibitors63010002118RX-86Non-nucleoside reverse transcriptase inhibitors67263043460RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase inhibitors67263056830RX-86Non-nucleoside reverse transcriptase inhibitors67263056830RX-86Non-nucleoside reverse transcriptase inhibitors68258902001RX-86Non-nucleoside reverse transcriptase inhibitors68258902101		Non-nucleoside reverse transcriptase inhibitors	54868452000
RX-86Non-nucleoside reverse transcriptase inhibitors55289039203RX-86Non-nucleoside reverse transcriptase inhibitors55289039263RX-86Non-nucleoside reverse transcriptase inhibitors59676057001RX-86Non-nucleoside reverse transcriptase inhibitors63010002036RX-86Non-nucleoside reverse transcriptase inhibitors63010002118RX-86Non-nucleoside reverse transcriptase inhibitors67263043460RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase inhibitors67263056830RX-86Non-nucleoside reverse transcriptase inhibitors68258902001RX-86Non-nucleoside reverse transcriptase inhibitors68258902101			
RX-86Non-nucleoside reverse transcriptase inhibitors55289039263RX-86Non-nucleoside reverse transcriptase inhibitors59676057001RX-86Non-nucleoside reverse transcriptase inhibitors63010002036RX-86Non-nucleoside reverse transcriptase inhibitors63010002118RX-86Non-nucleoside reverse transcriptase inhibitors67263043460RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase inhibitors67263056830RX-86Non-nucleoside reverse transcriptase inhibitors68258902001RX-86Non-nucleoside reverse transcriptase inhibitors68258902101	RX-86	Non-nucleoside reverse transcriptase inhibitors	54868586400
RX-86Non-nucleoside reverse transcriptase inhibitors59676057001RX-86Non-nucleoside reverse transcriptase inhibitors63010002036RX-86Non-nucleoside reverse transcriptase inhibitors63010002118RX-86Non-nucleoside reverse transcriptase inhibitors67263043460RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase inhibitors67263056830RX-86Non-nucleoside reverse transcriptase inhibitors68258902001RX-86Non-nucleoside reverse transcriptase inhibitors68258902101	RX-86	Non-nucleoside reverse transcriptase inhibitors	
RX-86Non-nucleoside reverse transcriptase inhibitors63010002036RX-86Non-nucleoside reverse transcriptase inhibitors63010002118RX-86Non-nucleoside reverse transcriptase inhibitors67263043460RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase inhibitors67263056830RX-86Non-nucleoside reverse transcriptase inhibitors68258902001RX-86Non-nucleoside reverse transcriptase inhibitors68258902101	RX-86	Non-nucleoside reverse transcriptase inhibitors	
RX-86Non-nucleoside reverse transcriptase inhibitors63010002118RX-86Non-nucleoside reverse transcriptase inhibitors67263043460RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase inhibitors67263056830RX-86Non-nucleoside reverse transcriptase inhibitors68258902001RX-86Non-nucleoside reverse transcriptase inhibitors68258902101	RX-86		
RX-86Non-nucleoside reverse transcriptase inhibitors67263043460RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase inhibitors67263056830RX-86Non-nucleoside reverse transcriptase inhibitors68258902001RX-86Non-nucleoside reverse transcriptase inhibitors68258902101			63010002036
RX-86Non-nucleoside reverse transcriptase inhibitors67263045836RX-86Non-nucleoside reverse transcriptase inhibitors67263056830RX-86Non-nucleoside reverse transcriptase inhibitors68258902001RX-86Non-nucleoside reverse transcriptase inhibitors68258902101			
RX-86Non-nucleoside reverse transcriptase inhibitors67263056830RX-86Non-nucleoside reverse transcriptase inhibitors68258902001RX-86Non-nucleoside reverse transcriptase inhibitors68258902101			
RX-86Non-nucleoside reverse transcriptase inhibitors68258902001RX-86Non-nucleoside reverse transcriptase inhibitors68258902101	RX-86		
RX-86 Non-nucleoside reverse transcriptase inhibitors 68258902101			
	RX-86		
Rx code set Rx code set description ndc	RX-86	Non-nucleoside reverse transcriptase inhibitors	68258902101
KX code set is code set description ndc	Dec. 1	and December and december 2010	
	KX code	set KX code set description ndc	

NQF #PSM-026-10

			-
RX-102	Ritonavir	00074194063	
RX-102	Ritonavir	00074663322	
RX-102	Ritonavir	00074663330	
RX-102 RX-102	Ritonavir	00074949202	
RX-102	Ritonavir	00074949254	
RX-102	Ritonavir	35356013830	
RX-102	Ritonavir	54569433500	
RX-102	Ritonavir	54569461300	
RX-102	Ritonavir	54569479200	
RX-102	Ritonavir	54569565600	
RX-102	Ritonavir	54868378200	
RX-102	Ritonavir	54868378201	
RX-102	Ritonavir	54868378202	
RX-102 RX-102	Ritonavir		
RA-102	RILUIIAVII	54868378203	
	et Rx code set description	ndc	
RX-103	Lopinavir / Ritonavir	00074052260	
RX-103	Lopinavir / Ritonavir	00074395646	
RX-103	Lopinavir / Ritonavir	00074395977	
RX-103	Lopinavir / Ritonavir	00074679922	
RX-103	Lopinavir / Ritonavir	21695036212	
RX-103	Lopinavir / Ritonavir	35356011160	
RX-103	Lopinavir / Ritonavir	35356011201	
RX-103	Lopinavir / Ritonavir	35356011230	
RX-103	Lopinavir / Ritonavir	52959096812	
RX-103		54569514200	
	Lopinavir / Ritonavir		
RX-103	Lopinavir / Ritonavir	54569552500	
RX-103	Lopinavir / Ritonavir	54569575200	
RX-103	Lopinavir / Ritonavir	54868452400	
RX-103	Lopinavir / Ritonavir	54868556600	
RX-103	Lopinavir / Ritonavir	55045348201	
RX-103	Lopinavir / Ritonavir	55289093118	
RX-103	Lopinavir / Ritonavir	55289094712	
RX-103	Lopinavir / Ritonavir	67263023212	
Rx code s	et Rx code set description	ndc	
RX-104	Saguinavir	00004024451	
RX-104	Saquinavir	00004024515	
RX-104		00004024648	
	Saquinavir		
RX-104	Saquinavir	54569424200	
RX-104	Saquinavir	54569424201	
RX-104	Saquinavir	54569424202	
RX-104	Saquinavir	54569424203	
RX-104	Saquinavir	54569456300	
RX-104	Saquinavir	54569456301	
RX-104	Saquinavir	54569566400	
RX-104	Saguinavir	54868369900	
RX-104	Saquinavir	54868369901	
RX-104	Saguinavir	54868369902	
RX-104	Saquinavir	54868411000	
RX-104	Saquinavir	62682101802	
		62682101802	
RX-104	Saquinavir	02002101009	
Dy and -	ot. Dy code act description		
	et Rx code set description	ndc	
RX-112	Stavudine	00003196401	
RX-112	Stavudine	00003196501	
RX-112	Stavudine	00003196601	
RX-112	Stavudine	00003196701	
L			

RX-129	Zidovudine-containing medication	00081010793	
RX-129	Zidovudine-containing medication	00054005221	
	et Rx code set description	ndc	
RX-115	Tenofovir-containing medication	68258900301	
RX-115	Tenofovir-containing medication	67263045530	
RX-115	Tenofovir-containing medication	67263026030	
RX-115	Tenofovir-containing medication	61958070101	
RX-115	Tenofovir-containing medication	61958040101	
RX-115	Tenofovir-containing medication	55045348103	
RX-115	Tenofovir-containing medication	54868514100	
RX-115	Tenofovir-containing medication	54868466900	
RX-115	Tenofovir-containing medication	54569580500	
RX-115	Tenofovir-containing medication	54569558800	
RX-115	Tenofovir-containing medication	54569533400	
RX-115	Tenofovir-containing medication	52959096903	
RX-115	Tenofovir-containing medication	35356007330	
RX-115 RX-115	Tenofovir-containing medication	353560070306	
RX-115 RX-115	Tenofovir-containing medication	35356007006	
RX-115 RX-115	Tenofovir-containing medication	35356006430 35356007006	
RX-115 RX-115	Tenofovir-containing medication Tenofovir-containing medication	35356006406	
RX-115	Tenofovir-containing medication	15584010101	
	et Rx code set description	ndc	
RX-112	Stavudine	68258912601	
RX-112	Stavudine	68115036006	
RX-112	Stavudine	67253076120	
RX-112	Stavudine	65862011260	
RX-112	Stavudine	65862011160	
RX-112	Stavudine	65862004760	
RX-112	Stavudine	65862004660	
RX-112	Stavudine	59762119301	
RX-112	Stavudine	59762119201	
RX-112	Stavudine	59762119101	
RX-112	Stavudine	59762119001	
RX-112	Stavudine	54868344800	
RX-112	Stavudine	54868336000	
RX-112	Stavudine	54868335300	
RX-112	Stavudine	54868335201	
RX-112	Stavudine	54868335200	
RX-112	Stavudine	54569548000	
RX-112	Stavudine	54569541200	
RX-112 RX-112	Stavudine	54569538700	
RX-112	Stavudine	54569405400	
RX-112 RX-112	Stavudine	54569405400 54569405400	
RX-112 RX-112	Stavudine	54569405300	
RX-112 RX-112	Stavudine	35356028560	
RX-112 RX-112	Stavudine	35356007460	
RX-112 RX-112	Stavudine Stavudine	31722051760 31722051860	
RX-112	Stavudine	31722051660	
RX-112	Stavudine	31722051560	
RX-112	Stavudine	00378504391	
RX-112	Stavudine	00378504291	
RX-112	Stavudine	00378504191	
RX-112	Stavudine	00378504091	
RX-112	Stavudine	00003196801	

RX-129	Zidovudine-containing medication	00081010855
RX-129	Zidovudine-containing medication	00081010856
RX-129	Zidovudine-containing medication	00081011318
RX-129	Zidovudine-containing medication	00093553006
RX-129	Zidovudine-containing medication	00173010793
		00173010855
RX-129	Zidovudine-containing medication	
RX-129	Zidovudine-containing medication	00173010856
RX-129	Zidovudine-containing medication	00173011318
RX-129	Zidovudine-containing medication	00173050100
RX-129	Zidovudine-containing medication	00173059500
RX-129	Zidovudine-containing medication	00173059502
RX-129	Zidovudine-containing medication	00173069100
RX-129	Zidovudine-containing medication	00173069120
RX-129	Zidovudine-containing medication	00378610691
RX-129	Zidovudine-containing medication	16590006106
RX-129	Zidovudine-containing medication	21695036918
RX-129	Zidovudine-containing medication	21695084606
RX-129	Zidovudine-containing medication	23490708706
RX-129	Zidovudine-containing medication	31722050960
RX-129	Zidovudine-containing medication	35356011606
RX-129	Zidovudine-containing medication	35356011660
RX-129	Zidovudine-containing medication	49999006206
RX-129	Zidovudine-containing medication	49999006210
RX-129	Zidovudine-containing medication	49999006260
RX-129	Zidovudine-containing medication	49999038618
RX-129	Zidovudine-containing medication	50962045010
RX-129	Zidovudine-containing medication	50962045205
RX-129	Zidovudine-containing medication	52959038706
RX-129	Zidovudine-containing medication	52959050906
RX-129	Zidovudine-containing medication	52959050912
RX-129	Zidovudine-containing medication	52959050918
RX-129	Zidovudine-containing medication	52959050920
RX-129	Zidovudine-containing medication	52959050924
RX-129	Zidovudine-containing medication	52959050928
RX-129	Zidovudine-containing medication	52959050930
RX-129	Zidovudine-containing medication	52959054602
RX-129	Zidovudine-containing medication	52959054603
RX-129	Zidovudine-containing medication	52959054604
RX-129	Zidovudine-containing medication	52959054606
RX-129	Zidovudine-containing medication	52959054608
RX-129	Zidovudine-containing medication	52959054610
RX-129 RX-129	Zidovudine-containing medication	52959054614
RX-129 RX-129	Zidovudine-containing medication	52959054615
RX-129 RX-129		
	Zidovudine-containing medication	52959054620 52059054628
RX-129	Zidovudine-containing medication	52959054628 54560177200
RX-129	Zidovudine-containing medication	54569177200
RX-129	Zidovudine-containing medication	54569177201
RX-129	Zidovudine-containing medication	54569177202
RX-129	Zidovudine-containing medication	54569177203
RX-129	Zidovudine-containing medication	54569177204
RX-129	Zidovudine-containing medication	54569177205
RX-129	Zidovudine-containing medication	54569433400
RX-129	Zidovudine-containing medication	54569452400
RX-129	Zidovudine-containing medication	54569452401
RX-129	Zidovudine-containing medication	54569452402
RX-129	Zidovudine-containing medication	54569452403
RX-129	Zidovudine-containing medication	54569453800
RX-129	Zidovudine-containing medication	54569519100
·		

		-
RX-129	Zidovudine-containing medication	54868197400
RX-129	Zidovudine-containing medication	54868197402
RX-129	Zidovudine-containing medication	54868197403
RX-129	Zidovudine-containing medication	54868250401
RX-129	Zidovudine-containing medication	54868411400
RX-129	Zidovudine-containing medication	54868411406
RX-129	Zidovudine-containing medication	55045285606
RX-129	Zidovudine-containing medication	55045354901
RX-129	Zidovudine-containing medication	55175449401
RX-129	Zidovudine-containing medication	55175520706
RX-129		
	Zidovudine-containing medication	55289038904
RX-129	Zidovudine-containing medication	55289038906
RX-129	Zidovudine-containing medication	55289038914
RX-129	Zidovudine-containing medication	55289038920
RX-129	Zidovudine-containing medication	55887023130
RX-129	Zidovudine-containing medication	55887023160
RX-129	Zidovudine-containing medication	55887023190
RX-129	Zidovudine-containing medication	58016069000
RX-129	Zidovudine-containing medication	58016069018
RX-129	Zidovudine-containing medication	58016069030
RX-129	Zidovudine-containing medication	58016069060
RX-129	Zidovudine-containing medication	58016069090
RX-129	Zidovudine-containing medication	58016069800
RX-129	Zidovudine-containing medication	58016069830
RX-129	Zidovudine-containing medication	58016069860
RX-129	Zidovudine-containing medication	58016069890
RX-129	Zidovudine-containing medication	58016086400
RX-129	Zidovudine-containing medication	58016086430
RX-129	Zidovudine-containing medication	58016086460
RX-129		58016086490
	Zidovudine-containing medication	
RX-129	Zidovudine-containing medication	58864046230
RX-129	Zidovudine-containing medication	58864046260
RX-129	Zidovudine-containing medication	58864046293
RX-129	Zidovudine-containing medication	59762365001
RX-129	Zidovudine-containing medication	60760059504
RX-129	Zidovudine-containing medication	60760059514
RX-129	Zidovudine-containing medication	62682101501
RX-129	Zidovudine-containing medication	62682101502
RX-129	Zidovudine-containing medication	62682104801
RX-129	Zidovudine-containing medication	63304092060
RX-129	Zidovudine-containing medication	65862002460
RX-129	Zidovudine-containing medication	65862004824
RX-129	Zidovudine-containing medication	65862010701
RX-129	Zidovudine-containing medication	66267050906
RX-129	Zidovudine-containing medication	67253010910
RX-129	Zidovudine-containing medication	67253096124
RX-129	Zidovudine-containing medication	67263051401
RX-129	Zidovudine-containing medication	68030605901
RX-129	Zidovudine-containing medication	68030606501
RX-129	Zidovudine-containing medication	68030728301
RX-129	Zidovudine-containing medication	68115009006
RX-129	Zidovudine-containing medication	68258915801
Rx code s	et Rx code set description	ndc
RX-169	Emtricitabine-containing medication	15584010101
RX-169	Emtricitabine-containing medication	35356006406
RX-169	Emtricitabine-containing medication	35356006430
RX-169	Emtricitabine-containing medication	35356007006
107	Enterentabilité containing incultation	33330007000

RX-169	Emtricitabine-containing medica	ation 35356007030	
RX-169	Emtricitabine-containing medica	ation 35356020530	
X-169	Emtricitabine-containing medica	ation 52959096903	
X-169	Emtricitabine-containing medica	ation 54569552100	
X-169	Emtricitabine-containing medica	ation 54569558800	
X-169	Emtricitabine-containing medica	ation 54569580500	
X-169	Emtricitabine-containing medica	ation 54868485300	
X-169	Emtricitabine-containing medica		
x code s	et Rx code set description	ndc	
X-206	Tipranavir	00597000201	
X-206	Tipranavir	00597000302	
	et Rx code set description	ndc	
X-230	Darunavir	35356011301	
X-230	Darunavir	35356011330	
X-230	Darunavir	35356028460	
X-230	Darunavir	54569581400	
X-230	Darunavir	54868563100	
X-230	Darunavir	54868596900	
X-230	Darunavir	59676056001	
X-230	Darunavir	59676056101	
X-230	Darunavir	59676056201	
X-230	Darunavir	59676056301	
X-230	Darunavir	59676056401	
RX-230	Darunavir	67263059060	
	et Rx code set description	ndc	
X-404	Raltegravir	00006022761	
X-404	Raltegravir	35356011006	
X-404	Raltegravir	35356011060	
X-404	Raltegravir	54569603400	
X-404	Raltegravir	54868011700	
x code s	et Rx code set description	ndc	
X-405	Maraviroc	00069080760	
X-405	Maraviroc	00069080860	
X-405	Maraviroc	35356020860	
X-405	Maraviroc	35356020960	
X-405	Maraviroc	54569614300	
X-405	Maraviroc	54868580900	
X-405	Maraviroc	67263040260	

2a.10 Denominator Exclusion Details (*All information required to collect exclusions to the denominator, including all codes, logic, and definitions***):** Does not apply

2a.11 Stratification Details/Variables (*All information required to stratify the measure including the stratification variables, all codes, logic, and definitions***):** Does not apply

2a.12-13 Risk Adjustment Type: no risk adjustment necessary

2a.14 Risk Adjustment Methodology/Variables (*List risk adjustment variables and describe conceptual models, statistical models, or other aspects of model or method***):**

2a.15-17 Detailed risk model available Web page URL or attachment:

2a.18-19 Type of Score: rate/proportion

2a.20 Interpretation of Score: better quality = higher score

2a.21 Calculation Algorithm (Describe the calculation of the measure as a flowchart or series of steps): 1. Exclude members who meet denominator exclusion criteria

2. Assign a YES or NO result to remaining members based on numerator response

3. Rate = YES/[YES+NO]

2a.22 Describe the method for discriminating performance (e.g., significance testing): Our initial measure identified CBC monitoring in HIV-infected patients taking an AZT-containing HAART regimens (a subset of patient on HAART). Testing of this original measure nearly 1300 patients who met the denominator definition from a geographically diverse 15 million member benchmark database. Approximately 700 patients did not meet numerator compliance, indicating a significant population with patient safety gap in care. The subsequent compliance rate was 44.4 percent.

During the recent consultant panel review, this measure was revised based on the updated DHHS guidelines. Previous HIV/AIDS management guidelines recommended CBC testing for patients taking an AZT-containing HAART regimen. The more recent guidelines recommended CBC monitoring for any patient taking HAART. This measure was updated to reflect that change. This modification has been tested in our smaller CAT database. In this testing, 618 HIV-infected patients were identified based on our inclusion criteria and 94 meet the new denominator definition for this measure; the compliance rate was 42.6 percent. Benchmark results for this revised measure will be available in late 2010.

2a.23 Sampling (Survey) Methodology *If measure is based on a sample (or survey), provide instructions for obtaining the sample, conducting the survey and guidance on minimum sample size (response rate):* A 15 million patient population sample was chosen to analyze the potential patient safety gap in care. The sample was derived from more than 60 million patients based on criteria including national geographic representation, commercial health coverage and patient age less than 65.

2a.24 Data Source (*Check the source(s) for which the measure is specified and tested***)** Electronic adminstrative data/claims, lab data, pharmacy data

2a.25 Data source/data collection instrument (Identify the specific data source/data collection instrument, e.g. name of database, clinical registry, collection instrument, etc.): Our data source is a proprietary Ingenix provider database that includes more than 60 million patients, over multiple years. It includes data from multiple payors. This measure specifically uses the following data from this database: member demographics, ICD-9 codes, revenue codes, CPT codes, place of service codes, and pharmacy claims.

2a.26-28 Data source/data collection instrument reference web page URL or attachment:

2a.29-31 Data dictionary/code table web page URL or attachment: Attachment Input Guide_NQF-633991711815337262.doc

2a.32-35 Level of Measurement/Analysis (Check the level(s) for which the measure is specified and tested)

Clinicians: Individual, Clinicians: Group, Can be measured at all levels, Health Plan, Integrated delivery system, Program: Disease management, Program: QIO, Facility/Agency, Multi-site/corporate chain, Population: states, Population: counties or cities

	020 10
2a.36-37 Care Settings (<i>Check the setting(s) for which the measure is specified and tested)</i> nursing home (NH) /Skilled Nursing Facility (SNF), Rehabilitation Facility, Ambulatory Care: Clinic, Ambulatory Care: Emergency Dept, Ambulatory Care: Hospital Outpatient	
2a.38-41 Clinical Services (Healthcare services being measured, check all that apply) Clinicians: Physicians (MD/DO), Clinicians: PA/NP/Advanced Practice Nurse	
TESTING/ANALYSIS	
2b. Reliability testing	
2b.1 Data/sample (<i>description of data/sample and size</i>): Reliability is tested by using multiple databases. There are three primary databases that we use: 1) a customer acceptance (CAT) database that includes approximately 4000 members who satisfy the condition confirmation criteria; 2) a one million member face validity testing (FVT) database that is geographically diverse; and 3) a 15 million member benchmark database that is geographically diverse. All databases represent predominately a commercial population less than 65 year of age.	
2b.2 Analytic Method (type of reliability & rationale, method for testing): Quality assurance of each measure is accomplished through the testing using multiple methods and databases. Types of testing, data samples and volume vary to ensure the integrity of the measure. Rigorous development, analysis and testing processes are deployed for creating measure specifications. Software testing ensures the software is working as designed. Reliability and validity testing of measures is based on differing data samples and volume of members. National benchmarks are created on a large volume set of data representing members throughout the United States. All quality checks for all measure results must have consistent results and meet expected outcomes based on industry knowledge and experience.	
Customer Acceptance Testing (CAT) is an important quality process. CAT ensures that the clinical measures are functioning as intended and that they generate accurate results for typical billing patterns. Using actual claims data a team of business analysts, nurses, and health services researchers conducts a detailed analysis of the output. For each clinical condition in the product (e.g., Diabetes Mellitus, Coronary Artery Disease, etc.) there is a set of CAT data with at least 4000 members who satisfy the condition confirmation criteria. This data is extracted from a large (50+ million member) multi-payer benchmark database and contains inpatient, outpatient, pharmacy, and laboratory data. The testing team analyzes claims from individual members and compares the creation of denominators (target population), numerators, and exclusions from this manual review process to output results from the quality measure.	
Regression testing is the part of CAT that verifies the reliability of the product across software releases. For a new release the testing team confirms that every unchanged measure produces the same results as in previous releases, accounting for systematic changes to the software (e.g., code updates, logic changes, etc). Regression testing is conducted at multiple points throughout the software development cycle.	
2b.3 Testing Results (reliability statistics, assessment of adequacy in the context of norms for the test conducted): Given the size of our benchmark database, it is the most reliable source for compliance results. Over 4200 members from the benchmark database met the denominator definition for this measure. The overall compliance rate was 44.4 percent.	2b C P M N
2c. Validity testing	
2c.1 Data/sample (description of data/sample and size): Our data sample for face validity testing includes a geographically diverse one million member database. Our data sample for benchmark testing includes a geographically diverse 15 million member database. Both databases represent predominately a commercial population less than 65 year of age.	2c C□
2c.2 Analytic Method (type of validity & rationale, method for testing): Face Validity Testing (FVT) is the final testing step in the software release cycle. One million members are randomly selected from the large multi-payer benchmark database and their claims data is processed	C P M N

 through the software. The Medical Director reviews the results to verify that: 1. Prevalence rates for a condition are comparable to nationally published rates 2. Compliance rates for a measure are comparable to the rates reported in the published literature or by other national sources (e.g. HEDIS). If no comparable sources are available, the rates are judged based on what is clinically reasonable. In addition, all results are reviewed for face validity by members of an external physician clinical consultant panel. 	
A similar review of benchmark test results occurs in conjunction with a software release. With benchmark testing, 15 million members are randomly selected from the large multi-payer benchmark database and their claims data is processed through the software.	
Our claims-based measures have been validated using a chart review comparison process. This validation project is summarized below: Goal: evaluate the reliability of claims-based measure results using chart review as the gold standard Methods:	
The charts of 100 members from two clinics in one city were reviewed. Results from our claims-based measures were compared to information present in the chart. During this process, 726 measures were evaluated. Results:	
The overall error rate was less than 5%. The error rate varied depending on the type of claim required for numerator compliance and is summarized as follows: o The error rate was highest with medications, with an 11 percent error rate (2/18). From chart review, it was difficult to tell if this represented a real error, a medication sample was provided, or the prescription	
was never filled). o The error rate was 4 percent (14/318) for measures that required labs for numerator compliance. It was noted that a claims-based measure approach sometimes identified labs that were missing in chart review. o The error rate for office visit and specialty appointments was 2 percent (8/390). Of note, administrative claims was more likely than chart review to identify relevant office and specialty visits, particularly for appointments that occurred outside the clinic or network.	
o Errors were found related to coding in claims data, not due to the claims-based measures or methodology. These errors were not quantified.	
2c.3 Testing Results (statistical results, assessment of adequacy in the context of norms for the test conducted): Summarized in 2b3	
2d. Exclusions Justified	0
2d.1 Summary of Evidence supporting exclusion(s): This measure does not include any exclusions.	
2d.2 Citations for Evidence:	
2d.3 Data/sample (description of data/sample and size):	2d
2d.4 Analytic Method (type analysis & rationale):	C P
2d.5 Testing Results (e.g., frequency, variability, sensitivity analyses):	
2e. Risk Adjustment for Outcomes/ Resource Use Measures	2e
2e.1 Data/sample (description of data/sample and size): This measure does not include risk adjustment.	

2e.2 Analytic Method (type of risk adjustment, analysis, & rationale):	N NA			
2e.3 Testing Results (risk model performance metrics):				
2e.4 If outcome or resource use measure is not risk adjusted, provide rationale:				
2f. Identification of Meaningful Differences in Performance				
2f.1 Data/sample from Testing or Current Use (description of data/sample and size): Our benchmark data sample includes a geographically diverse 15 million member benchmark database. The database represents predominately a commercial population less than 65 year of age.				
2f.2 Methods to identify statistically significant and practically/meaningfully differences in performance (type of analysis & rationale):				
During benchmark testing, 15 million members are randomly selected from the large multi-payer benchmark database and their claims data is processed through the software. The Medical Director reviews the results to verify that:				
 Prevalence rates for a condition are comparable to nationally published rates Compliance rates for a measure are comparable to the rates reported in the published literature or by other national sources (e.g. HEDIS). If no comparable sources are available, the rates are judged based on what is clinically reasonable. 				
In addition, all results are systematically reviewed for face validity by members of an external physician clinical consultant panel.				
	2f			
2f.3 Provide Measure Scores from Testing or Current Use (description of scores, e.g., distribution by quartile, mean, median, SD, etc.; identification of statistically significant and meaningfully differences in performance): Summarized in 2b3	C P M N			
2g. Comparability of Multiple Data Sources/Methods				
2g.1 Data/sample (description of data/sample and size):				
2g.2 Analytic Method (type of analysis & rationale):	2g C P			
2g.3 Testing Results (e.g., correlation statistics, comparison of rankings):	M N NA			
2h. Disparities in Care	2h			
2h.1 If measure is stratified, provide stratified results (scores by stratified categories/cohorts):	C P			
2h.2 If disparities have been reported/identified, but measure is not specified to detect disparities, provide follow-up plans:	M N NA			
TAP/Workgroup: What are the strengths and weaknesses in relation to the sub-criteria for Scientific Acceptability of Measure Properties?	2			
Steering Committee: Overall, to what extent was the criterion, Scientific Acceptability of Measure	2			
Properties, met? Rationale:	C 🗌 P 🗌			
	M□ N□			
3. USABILITY				

Extent to which intended audiences (e.g., consumers, purchasers, providers, policy makers) can understand the results of the measure and are likely to find them useful for decision making. (<u>evaluation criteria</u>)	Eval Ratin g
3a. Meaningful, Understandable, and Useful Information	1
3a.1 Current Use: in use	
3a.2 Use in a public reporting initiative (disclosure of performance results to the public at large) (<i>If used in a public reporting initiative, provide name of initiative(s), locations, Web page URL(s).</i> <u><i>If not publicly reported, state the plans to achieve public reporting within 3 years</i>): Health plans, physicians (individuals and groups), care management, and other vendors/customers are using</u>	
this measure on a national level. However, we do not know if this specific measure is being used as part of a public reporting initiative.	
3a.3 If used in other programs/initiatives (<i>If used in quality improvement or other programs/initiatives, name of initiative(s), locations, Web page URL(s).</i> <u><i>If not used for QI, state the plans to achieve use for QI within 3 years</i>):</u>	
Health plans, physicians (individuals and groups), care management, and other vendors/customers use many of our measures on a national level for quality improvement, disease management, and physician sharing programs. Customers are able to select their measures depending on their business needs. As such, we do not know which specific measures are used by our customers.	
Testing of Interpretability (Testing that demonstrates the results are understood by the potential users for public reporting and quality improvement)	
3a.4 Data/sample (description of data/sample and size): Results are summarized and reported by users/customers depending on their business need - we do not have access to this information. Because of us my multiple users/customers, there is no single data sample, methodology, or public reporting format.	
3a.5 Methods (e.g., focus group, survey, QI project):	3a C 🗌 P 🗌
3a.6 Results (qualitative and/or quantitative results and conclusions):	M N
3b/3c. Relation to other NQF-endorsed measures	
3b.1 NQF # and Title of similar or related measures:	
(for NQF staff use) Notes on similar/related <u>endorsed</u> or submitted measures:	
 3b. Harmonization If this measure is related to measure(s) already <u>endorsed by NQF</u> (e.g., same topic, but different target population/setting/data source <u>or</u> different topic but same target population): 3b.2 Are the measure specifications harmonized? If not, why? 	3b C P M N
3c. Distinctive or Additive Value	
3c.1 Describe the distinctive, improved, or additive value this measure provides to existing NQF- endorsed measures:	
5.1 Competing Measures If this measure is similar to measure(s) already endorsed by NQF (i.e., on the same topic and the same target population), describe why it is a more valid or efficient way to measure quality:	3c C P M N
TAP/Workgroup: What are the strengths and weaknesses in relation to the sub-criteria for Usability?	3

Steering Committee: Overall, to what extent was the criterion, <i>Usability</i> , met? Rationale:	3 C P M N
4. FEASIBILITY	
Extent to which the required data are readily available, retrievable without undue burden, and can be implemented for performance measurement. (<u>evaluation criteria</u>)	Eval Ratin g
4a. Data Generated as a Byproduct of Care Processes	4a
4a.1-2 How are the data elements that are needed to compute measure scores generated? coding/abstraction performed by someone other than person obtaining original information,	C P M N
4b. Electronic Sources	
4b.1 Are all the data elements available electronically? (elements that are needed to compute measure scores are in defined, computer-readable fields, e.g., electronic health record, electronic claims) Yes	4b C□ P□
4b.2 If not, specify the near-term path to achieve electronic capture by most providers.	M N
4c. Exclusions	
4c.1 Do the specified exclusions require additional data sources beyond what is required for the numerator and denominator specifications? No	4c C P M N
4c.2 If yes, provide justification.	
4d. Susceptibility to Inaccuracies, Errors, or Unintended Consequences	
4d.1 Identify susceptibility to inaccuracies, errors, or unintended consequences of the measure and describe how these potential problems could be audited. If audited, provide results. It is possible that some CBC claims could be missed if obtained during a hospitalization. However, the guideline recommendation is for CBC testing every 3-6 months and numerator compliance for our measure will be met if the test was done during the last 6 months of the report period through 90 days after the report period (a 9 month total time period). We believe that our 9 month timeframe minimizes the likelihood that this error would impact the compliance results.	4d C P M N
4e. Data Collection Strategy/Implementation	
4e.1 Describe what you have learned/modified as a result of testing and/or operational use of the measure regarding data collection, availability of data/missing data, timing/frequency of data collection, patient confidentiality, time/cost of data collection, other feasibility/ implementation issues:	
No modifications have been necessary based on testing or operational use of this measure.	
Modifications were made during the last consultant panel review based on the updated DHHS guidelines. Previous HIV/AIDS management guidelines recommended CBC testing for patients taking an AZT-containing HAART regimen. The more recent guidelines have recommended CBC monitoring for any patient taking HAART. This measure was updated to reflect that change.	4e C□ P□
4e.2 Costs to implement the measure (costs of data collection, fees associated with proprietary measures):	 M N

	020 10
We do not have access to this information. This would vary based on the customer/vendor, patient population, and programs/interventions associated with measure use.	
4e.3 Evidence for costs:	
4e.4 Business case documentation:	
TAP/Workgroup: What are the strengths and weaknesses in relation to the sub-criteria for Feasibility?	4
Steering Committee: Overall, to what extent was the criterion, <i>Feasibility</i> , met? Rationale:	4 C P M N
RECOMMENDATION	
(for NQF staff use) Check if measure is untested and only eligible for time-limited endorsement.	Time- limited
Steering Committee: Do you recommend for endorsement? Comments:	Y N A
CONTACT INFORMATION	
Co.1 Measure Steward (Intellectual Property Owner) Co.1 <u>Organization</u> Ingenix 12125 Technology Drive Eden Prairie Minnesota 55344 Co.2 <u>Point of Contact</u> Kay Schwebke, Medical Director kay.schwebke@ingenix.com 952-833-7154	
Measure Developer If different from Measure Steward Co.3 Organization Ingenix 12125 Technology Drive Eden Prairie Minnesota 55344 Co.4 Point of Contact Kay Schwebke, Medical Director kay.schwebke@ingenix.com 952-833-7154	
Co.5 Submitter If different from Measure Steward POC Kay Schwebke, Medical Director kay.schwebke@ingenix.com 952-833-7154- Ingenix	
Co.6 Additional organizations that sponsored/participated in measure development This measure has been reviewed and supported by a quality subcommittee organized by the Infectious Diseas Society of America (IDSA) and consisting of IDSA members.	ies
ADDITIONAL INFORMATION	
 Workgroup/Expert Panel involved in measure development Ad.1 Provide a list of sponsoring organizations and workgroup/panel members' names and organizations. Describe the members' role in measure development. We have an external consultant panel that participates in the original literature search process, measure development, code set review, testing review, and maintenance processes. Panel members include the follow NAME & Title Employer/Position Alexander, Beth Pharm D, BCPS Assistant Professor, Augsburg College Ayenew, Woubeshet, MD Hennepin Faculty Associates; Hennepin County Medical Center Becker, Keith, MD Fairview Medical Center Betcher, Susan, MD Allina Medical Clinic 	

Bruer, Paul, MD Comprehensive Ophthamology, LLC Capecchi, Joseph, MD Allina Medical Clinic Giesler, Janell, MD Allina Medical Clinic Grabowski, Carol, MD Allina Medical Clinic Hansen, Calvin, MD Iowa Health Physicians Hargrove, Jody, MD Arthritis and Rheumatology Consultants Hermann, Richard, MD Tufts - New England Medical Center Jemming, Brian, Pharm D CentraCare Health System Kohen, Jeffrey, MD Veterans Affairs Medical Center McCarthy, Teresa, MD University of Minnesota, Department of Family Medicine & Community Health McEvoy, Charlene, MD, MPH HealthPartners & HealthPartners Research Foundation: Assistant Professor of Medicine, University of Minnesota McGee, Deanna, Pharm D, BCPS Retail Pharmacy Ogle, Kathleen, MD Hennepin Faculty Associates; Hennepin County Medical Center: Assistant Professor of Medicine, University of Minnesota Medical School Peter, Kathleen, MD Park Nicollet Medical Center Pieper-Bigelow, Christina, MD Allina Medical Clinic Redmon, Bruce, MD University of Minnesota Physicians Scharpf, Steven, MD Mountain Valleys Health Centers Weitz, Carol, MD Independent

Ad.2 If adapted, provide name of original measure: Ad.3-5 If adapted, provide original specifications URL or attachment

Measure Developer/Steward Updates and Ongoing Maintenance Ad.6 Year the measure was first released: 2006 Ad.7 Month and Year of most recent revision: 2009-03

Ad.7 Month and Year of most recent revision: 2009-03

Ad.8 What is your frequency for review/update of this measure? every 3 years at minimum Ad.9 When is the next scheduled review/update for this measure? 2012-03

Ad.10 Copyright statement/disclaimers: The information in this document is subject to change without notice. This documentation contains proprietary information, and is protected by U.S. and international copyright. All rights reserved. No part of this documentation may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, modifying, or recording, without the prior written permission of Ingenix, Inc. No part of this documentation may be translated to another program language without the prior written prior written consent of Ingenix, Inc.

© 2009 Ingenix, Inc.

HEDIS is a registered trademark of the National Committee for Quality Assurance (NCQA).

National Committee for Quality Assurance (NCQA) Notice:

HEDIS® 2009 Measure Specification: The HEDIS® measures and specifications were developed by and are owned by the National Committee for Quality Assurance ("NCQA"). The HEDIS measures and specifications are not clinical guidelines and do not establish standards of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures or any data or rates calculated using the HEDIS measures and specifications and NCQA has no liability to anyone who relies on such measures or specifications. © 2008 National Committee for Quality Assurance, all rights reserved.

The following rule types indicate NCQA HEDIS rules: NS-H and NSHA.

American Medical Association Notice:

CPT only © 2008 American Medical Association. All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice

medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. CPT is a registered trademark of the American Medical Association.

The following rule type indicates AMA rules: NS-A.

U.S. Government Rights:


This product includes CPT® and/or CPT® Assistant and/or CPT® Changes which is commercial technical data and/or computer data bases and/or commercial computer software and/or commercial computer software documentation, as applicable which were developed exclusively at private expense by the American Medical Association, 515 North State Street, Chicago, Illinois, 60610. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2) (November 1995) and/or subject to the restrictions of DFARS 227.7202-1(a) (June 1995), as applicable for U.S. Department of Defense procurements and the limited rights restrictions of FAR 52.227-14 (June 1987) and/or subject to the restricted rights provisions of FAR 52.227-14 (June 1987), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements.

Applicable FARS/DFARS Restrictions Apply to Government Use

CDT-4 codes and descriptions are © copyright 2008 American Dental Association. All rights reserved. Reproduction in any media of all or any portion of this work is strictly prohibited without the prior written consent of American Dental Association.

Ad.11 -13 Additional Information web page URL or attachment:

Date of Submission (MM/DD/YY): 01/22/2010



The information in this document is subject to change without notice. This documentation contains proprietary information, and is protected by U.S. and international copyright. All rights reserved. No part of this documentation may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, modifying, or recording, without the prior written permission of Ingenix, Inc. No part of this documentation may be translated to another program language without the prior written consent of Ingenix, Inc.

© 2008 Ingenix, Inc.

Release 7.0, Technical Guide for Windows, February 2008

National Committee for Quality Assurance (NCQA) Notice:

HEDIS 2007 Measure Specification

The HEDIS[®] measures and specifications were developed by and are owned by the National Committee for Quality Assurance ("NCQA"). The HEDIS measures and specifications are not clinical guidelines and do not establish standards of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures or any data or rates calculated using the HEDIS measures and specifications and NCQA has no liability to anyone who relies on such measures or specifications. ©2006 National Committee for Quality Assurance, all rights reserved.

'NS-H' and 'NSHA' indicate NCQA HEDIS rules.

HEDIS is a registered trademark of the National Committee for Quality Assurance (NCQA).

American Medical Association Notice:

CPT only © 2007 American Medical Association. All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

CPT is a registered trademark of the American Medical Association

'NS-A' indicates AMA rules.

U.S. Government Rights:

This product includes CPT[®] and/or CPT[®] Assistant and/or CPT[®] Changes which is commercial technical data and/or computer data bases and/or commercial computer software and/or commercial computer software documentation, as applicable which were developed exclusively at private expense by the American Medical Association, 515 North State Street, Chicago, Illinois, 60610. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2) (November 1995) and/or subject to the restrictions of DFARS 227.7202-1(a) (June 1995) and DFARS 227.7202-3(a) (June 1995), as applicable for U.S. Department of Defense procurements and the limited rights restrictions of FAR 52.227-14 (June 1987) and/or subject to the restricted rights provisions of FAR 52.227-14 (June 1987) and FAR 52.227-19 (June 1987), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements.

Applicable FARS/DFARS Restrictions Apply to Government Use.

CDT-4 codes and descriptions are © copyright 2007 American Dental Association. All rights reserved. Reproduction in any media of all or any portion of this work is strictly prohibited without the prior written consent of American Dental Association.

Ingenix 950 Winter Street, Suite 3800 Waltham, MA 02451 Customer Support: Tel: 866.818.7424 Fax: 781.895.9951 SymmetrySuite.Support@ingenix.com



What Input Files to Prepare

The following list specifies what input files you prepare for processing:

- The claims data file (required)
- The member data file (required) ٠
- The member term data file (required) ٠



Field Type Definitions and Input File Requirements

This chapter lists the field requirements for your input files. One of the attributes listed among the requirements is defined as "Type". There are four field types used to describe a field's value, and they are defined below.

Field Type	Definition
AlphaNum	A value made of letters and/or numbers. If a value of this type is made of numbers only, it will not be a value that can be operated on mathematically. For example, it would be inappropriate to subtract one procedure code from another procedure code even though both values may contain only numbers.
Num	A value made of numbers only, and which can logically be operated on mathematically. Age is an example of this type.
	One particular field, while not used in mathematical calculations, is defined in the EBM Connect software as such that it accepts only numeric values. (To enter a non-numeric value would cause EBM Connect processing to stop.) Therefore, this field is defined as Num. It is the Case ID field in the optional disease registry input file.
Date	A value which can be interpreted as a date value. Values should always use four-digit years but the format may vary otherwise.
DecNum	A value made of numbers and a decimal point. These values can also logically be operated on mathematically.

Claims Input File

The claims file contains detailed information on services that were billed or performed or otherwise rendered. The claims file includes:

- · Medical claims, including medical services, facility services and clinic services
- Pharmacy claims, including billed prescriptions and drugs
- · Lab claims, including lab test and results information

Field Name	Туре	Length	Required or Optional
Family ID	AlphaNum	1-30	Always required for all claims
Patient ID	AlphaNum	0-2	Optional
Amount Paid	DecNum	1-11	Required for all claims
Amount Allowed	DecNum	0-11	Required for all claims
Procedure Code	AlphaNum	5	Required if there is no revenue code, NDC, or LOINC® code
Procedure Code Modifier	AlphaNum	2	Required for medical claims
Revenue Code	AlphaNum	0 or 4	Optional (applies to medical claims when used)
First Diagnosis Code	AlphaNum	5 or 6	Required for medical claims
Second Diagnosis Code	AlphaNum	0, 5 or 6	Optional (applies to medical claims when used)
Third Diagnosis Code	AlphaNum	0, 5 or 6	Optional (applies to medical claims when used)
Fourth Diagnosis Code	AlphaNum	0, 5 or 6	Optional (applies to medical claims when used)
First Date of Service	Date	8 or 10	Always required for all claims
Last Date of Service	Date	8 or 10	Required for all claims

INGENIX.

Input Guide

Paid Date	Date	0, 8 or 10	Optional		
Type of Service	AlphaNum	0-10	Optional		
Provider ID	AlphaNum	1-20	Required for medical claims		
Ordering Provider ID	AlphaNum	0-20	Optional		
Provider Type	AlphaNum	1-10	Required for medical claims		
Provider Specialty Type	AlphaNum	1-10	Required for medical claims		
Provider Key	AlphaNum	1-20	Required for medical claims		
NDC	AlphaNum	0 or 11	Required for Rx claims		
Day Supply	Num	0-4	Required for Rx claims		
Quantity Count	DecNum	0-10	Required for Rx claims		
LOINC®	AlphaNum	0 or 7	Required for lab claims		
Lab Test Result	AlphaNum	0-18	Required for lab claims		
Place of Service	AlphaNum	1-10	Required for medical claims		
Unique Record ID	AlphaNum	1-28	Required for all claims		
Claim Number	AlphaNum	1-28	Required for all claims		
Bill Type Frequency Indicator	Num	0 or 1	Optional		
Patient Status	AlphaNum	1-2	Required for facility claims (involving admission or confinement).		
Facility Type	AlphaNum	0-2	Optional		
Bed Type	AlphaNum	0-1	Optional		
First ICD-9 Procedure Code	AlphaNum	0, 4 or 5	Optional, but will impact results (applies to medical claims whe used)		
Second ICD-9 Procedure Code	AlphaNum	0, 4 or 5	Optional (see above)		
Third ICD-9 Procedure Code	AlphaNum	0, 4 or 5	Optional (see above)		
Fourth ICD-9 Procedure Code	AlphaNum	0, 4 or 5	Optional (see above)		

Field Descriptions

Instructions for each input field are as follows:

Family ID

This field identifies all members of a family and can be any alphanumeric string.

Note: Remember that each Family ID (and Patient ID) listed in your claims input file must have a corresponding record in your member input data file and your member term data file.



Patient ID

This field identifies individual members within a family. If present, this field must be sorted within Family ID, so that all records for an individual are contiguous. If the Family ID uniquely identifies an individual, this field need not be specified (that is, its length in the dictionary will be zero).

Amount Paid

The amount paid for this claim line.

Amount Allowed

The allowed amount for this claim line. This amount typically represents the total amount reimbursed including deductibles, copays, coinsurance, insurer paid, etc.

Procedure Code

The procedure code must be one of:

- A procedure code specified in the Physician's Current Procedure Terminology, 4th Edition (CPT[®]-4 codes) defined by the American Medical Association, for the years 1997 and later.
- A procedure code specified by the HCFA Common Procedure Coding System, Level II code (HCPCS) defined by the Centers for Medicare and Medicaid Services (CMS) for the years 1999 and later.
- A National Uniform Billing Committee (NUBC) revenue code.

Note: When the NUBC code is entered in the Procedure Code field, it should be padded to the right with blanks because the Procedure Code field always occupies five characters.

If your organization defines its own procedure codes and/or revenue codes, they must be mapped to standard procedure and revenue codes.

Procedure Code Modifier

Use this field to specify any procedure code modifier that accompanies the procedure code.

Revenue Code

The revenue code, if one was entered for the claim. Supported values in this field are NUBC revenue codes. If your organization defines its own revenue codes, they must be mapped to standard revenue codes.

The revenue code is an optional field, allowing you to define your input records so that you can place an NUBC revenue code and a CPT/HCPCS procedure code on a single record line.

For claim records that do not have a revenue code, leave the revenue code field blank.

INGENIX. Input Guide

First Diagnosis Code Through Fourth Diagnosis Code

Up to four diagnoses may be entered for each claim, but only the first is required.

If your organization defines its own diagnosis codes, they must be mapped to standard ICD-9 diagnosis codes.

First Date of Service and Last Date of Service

The first date and last date represented by the claim line. If you choose to use a date format with separators (such as YYYY/MM/DD or YYYY-MM-DD), the separators are ignored on input, so you can use any character as a separator. Valid formats include: YYYYMMDD, MMDDYYYY, DDMMYYYY, YYYY/MM/DD, MM/DD/ YYYY, and DD/MM/YYYY, where the separator can be any character.

Paid Date

This field is optional. This is the date the claim was paid. The format of the paid date must be the same as that used in the First and Last Date of Service.

Type of Service

This is an optional code which represents the type of service (TOS) performed for this claim. If no specific value is available for this field, it should be filled with blanks. If this field is not used (i.e., its length is set to zero in the configuration), non-pharmaceutical claims with no procedure code will be treated as ancillary records.

Provider ID

Provider identification number from the claim. Used to identify who performed the service.

Ordering Provider ID

This is an optional field. This is the identification number of the provider who ordered the service.

Provider Type

This code represents the type of provider who performed the service. Examples of provider types would be chiropractor, nurse practitioner, medical doctor, counselor, pharmacy, hospital or treatment facility.

Provider Specialty Type

This code represents the specialty of the provider who performed the service.

Provider Key

Unique number or code for a physician who has multiple provider IDs or specialties. A single health care provider may have multiple provider IDs in your input claims data, but this person or entity should have only one provider key.

INGENIX.

Input Guide

NDC

If this is a pharmaceutical claim, this field should contain the drug's NDC code. For nonpharmaceutical claim records, the NDC field should be filled with blanks.

Day Supply

For pharmacy records, the number of days a filled prescription is expected to last. If you have no pharmacy records, the Days Supply is an optional field.

Quantity Count

Quantity of drug dispensed in metric units:

Each - solid oral dosage forms (tablet, capsule), powder filled (dry) vials, packets, patches, units of use packages, suppositories, bars.

Milliliter - (cc) liquid oral dosage forms, liquid filled vials, ampules, reconstituted oral products.

Grams - ointments, bulk powders (not IV). If you have no pharmacy records, the Quantity Count is an optional field.

LOINC®

Logical Observation Identifiers Names and Codes (LOINC[®]). The LOINC Code is a universal identifier for a lab test for a particular analyte. The LOINC User's Guide and database can be found at www.regenstrief.org.

Enter a LOINC code if the record is a lab record. For non-lab records, leave the LOINC field blank.

If you have no lab records in your claims input, the LOINC code is optional.

Notes:

- (1) When using lab results data that has not been mapped to a LOINC code, map the comparable vendor-specific test number provided by the laboratory vendor(s) to one of these default codes.
- (2) This is a retired code which may be present on historical data, or which some laboratories may be continuing to use. Input record data with this code is included in the definition of this test.

Lab Test Result

If the record is a lab record, use this field to enter the result value of lab test. For nonlab records, this field should be blank.

If you have no lab records in your claims input, the Lab Test Result is optional.

Place of Service

Place of service (POS). You must map your internal POS codes to Centers for Medicare and Medicaid Services (CMS) standard POS codes.

Page 8 of 12

Confidential and Proprietary. Recipient of this information may not disclose, permit to be disclosed, or otherwise resell or transfer all or any portion of this information to any third party. Input Guide_NQF-633991711815337262.doc



Input Guide

Unique Record ID

This required field contains a unique identifier representing the service line from the claim. For medical services, this ID typically represents the service row from the CMS 1500 or CMS 1450/UB92 claim form.

Claim Number

A unique identifier used to link service lines for a specific claim submitted for a member. If a claim has multiple service lines, each service will have a unique record ID and the same claim number to represent the claim.

Bill Type Frequency Indicator

This optional field is used to indicate the disposition of confinements.

Patient Status

This field is required for facility claims. The contents will be the patient status indicator field from the NUBC UB-92 form. This field can denote whether the member died during a confinement.

Facility Type

This field is optional. Space for it is provided to allow for additional post grouping analysis. The contents will typically be the UB-92 facility type data value. This would allow records to be easily selected for diagnosis related grouping (DRG) based on the facility type.

Bed Type

If a value is present, this field acts as an additional discriminator in determining whether a Facility record extends an existing confinement or starts a new confinement.

First ICD-9 Procedure Code Through Fourth ICD-9 Procedure Code

If your claims have ICD-9 procedure codes, include them in your claims input file.

If a decimal point will appear in this field in your claim records, the length should be given as 5. If the decimal separator is not used, the length is 4. If these fields are unused, the length is zero.

INGENIX. Input Guide

Member Input File

The member data file contains the most current information about the member.

Field Descriptions

Field	Туре	Length	Required or Optional
Family ID	AlphaNum	1-30	Required
Patient ID	AlphaNum	0-2	Optional
Patient Gender	AlphaNum	1	Required
Date of Birth	Date	8 or 10	Required
Member Beginning Eligibility Date	Date	0, 8 or 10	Optional
Member Ending Eligibility Date	Date	0, 8 or 10	Optional

Instructions for each input field are as follows:

Family ID

This field identifies all members of a family and can be any alphanumeric string. The records in the member file must be sorted first on the Family ID (together with Patient ID, if available) so that all records for an individual are contiguous.

Patient ID

This field identifies individual members within a family. If present, this field must be sorted within Family ID, so that all records for an individual are contiguous. If the Family ID uniquely identifies an individual, this field need not be specified (that is, its length in the dictionary will be zero).

Patient Gender and Date of Birth

The member's gender (F or M) and date of birth. If you choose to use a date format with separators (such as YYYY/MM/DD or YYYY-MM-DD), the separators are ignored on input, so you can use any character as a separator. Valid date formats include: YYYYMMDD, MMDDYYYY, DDMMYYYY, YYYY/MM/DD, MM/DD/YYYY, and DD/MM/YYYY, where the separator can be any character.

Member Beginning Eligibility Date and Ending Eligibility Date

The first date on which the member became covered under the plan and the last date of the member's coverage. If you choose to use a date format with separators (such as YYYY/MM/DD or YYYY-MM-DD), the separators are ignored on input, so you can use any character as a separator. Valid formats include: YYYYMMDD, MMDDYYYY, DDMMYYYY, YYYY/MM/DD, MM/DD/YYYY, and DD/MM/YYYY, where the separator can be any character.

Page 10 of 12 Confidential and Proprietary. Recipient of this information may not disclose, permit to be disclosed, or otherwise resell or transfer all or any portion of this information to any third party. Input Guide_NQF-633991711815337262.doc

INGENIX. Input Guide

Member Term Input File

The member term data file contains member coverage and term activity information. Plan coverage begin and end dates are required in order to correctly calculate the other fields in the member term file. There may be more than one record per individual member.

Field Descriptions

Field	Туре	Length	Required or Optional
Family ID	AlphaNum	1-30	Required
Patient ID	AlphaNum	0-2	Optional
Member Beginning Eligibility Date	Date	8 or 10	Required
Member Ending Eligibility Date	Date	8 or 10	Required
Primary Care Provider	AlphaNum	20	Required
Provider Specialty Type	AlphaNum	1-10	Required
Medical Flag	AlphaNum	1	Required
Pharmacy Flag	AlphaNum	1	Required

Instructions for each input field are as follows:

Family ID

This field identifies all members of a family and can be any alphanumeric string. The records in the member term file must be sorted first on the Family ID (together with Patient ID, if available) so that all records for an individual are contiguous.

Patient ID

This field identifies individual members within a family.

Member Beginning Eligibility Date and Member Ending Eligibility Date

The first date on which the member became covered under the plan and the last date of the member's coverage. If you choose to use a date format with separators (such as YYYY/MM/DD or YYYY-MM-DD), the separators are ignored on input, so you can use any character as a separator. Valid formats include: YYYYMMDD, MMDDYYYY, DDMMYYYY, YYYY/MM/DD, MM/DD/YYYY, and DD/MM/YYYY, where the separator can be any character.

Primary Care Provider

The provider key for the member's primary care physician. A single health care physician may have multiple provider IDs in your input claims data, but this person should have only one provider key.

INGENIX.

Input Guide

Provider Specialty Type

This code represents the specialty of the primary care physician.

Medical Flag

Identifies whether the member has medical coverage (Y or N).

Pharmacy Flag

Identifies whether the member has pharmacy coverage (Y or N).